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ABSTRACT 
 
Mechanisms of Retroviral Reverse Transcription and Assembly 
 
Sara Kirsten Rasmussen 
 
 The work described in these dissertation studies examines three aspects of 
retrovirus replication and dissects the uncovered phenomena to increase 
understanding of how retroviruses thrive in complex host environments. The first 
aspect of replication discussed is the mechanisms behind minus-strand DNA 
transfer, a crucial step of reverse transcription.  We proved for the first time that 
non-viral sequences can be utilized to carry out this step of the replication process, 
and that the minus-strand DNA transfer step can be exploited to reconstitute a 
functional gene in the infected host cell.  This finding serves as a proof-of-principle 
for a new class of self-activating gene therapy vectors.  In the second study, 
mechanisms of trans-complementation were studied between two distantly related 
retroviruses, murine leukemia virus (MLV) and spleen necrosis virus.  We showed 
that two different species of pol proteins can be incorporated into virions and 
cooperate to complete the reverse transcription and integration steps of replication.  
This finding highlights how different species of retroviruses could possibly interact 
and combine to form new and possibly more virulent or pathogenic species.  Finally, 
in the third work, a previously uninvestigated region of MLV capsid protein was 
examined.  Specifically, the contribution of the 33 carboxyl-terminal amino acids of 
MLV CA were found to consist of highly charged residues.  The contribution of 
these residues to virus assembly was investigated via deletion analysis.  A new 
phenotype of MLV CA assembly defect was demonstrated, and a structural model 
was proposed to explain the possible role of this region, termed the charged 
assembly helix, in MLV assembly.  In summary, the work presented in this 
dissertation has revealed new properties of retroviral replication as well as further 
clarified previous knowledge of retroviral biology. 
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INTRODUCTION 
 Worldwide, retroviruses affect a startling degree of human ecology and biology.  
Most notable of these viruses is human immunodeficiency virus type 1 (HIV-1), the 
retrovirus which causes Acquired Immune Deficiency Syndrome, or AIDS.  Currently 40 
million people are infected with HIV-1, a global epidemic that is devastating populations, 
especially in developing countries (21).  Available treatments are known as highly active 
antiretroviral therapy (HAART), and consist of combinations of antiretroviral drugs 
directed at different stages of the virus life cycle.  Treatments are often complicated by 
high toxicity and severe side effects.  HAART is able to block a certain percentage of 
viral replication but cannot eradicate HIV-1 from the infected host.  Eventually, HIV-1 
escapes every possible treatment regimen by its ability to rapidly mutate and recombine.  
Furthermore, the treatments that are available are only affordable in developed countries, 
such as the United States and Europe, where less than 1% (900,000 people in the United 
States) of the populations are infected.  HAART is not available in third world countries, 
where the infection rates in some places approach 40% or higher.  HAART is not 
available in the developing nations in Asia and Africa.  If no effective treatments for 
HIV-1 are found, everyone who is infected with this virus will eventually die of 
complications caused by it.  Research of HIV-1 is necessary to develop more viable 
therapies, and most importantly, a vaccine to halt the spread of HIV-1 in the population. 
AIDS alone is enough to mandate a call to retrovirology research.  However, 
retroviruses also cause cancer in humans and animals.  They can cause cancer by direct 
infection of cells, as in the case of human T-cell leukemia virus (HTLV) or murine 
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leukemia virus (MLV) (13, 18, 26, 33, 39, 40).  Retroviruses have also been 
demonstrated to capture and package oncogenes from the genome of the infected host 
and cause cancer by activating or altering these genes (49).  Increasingly, more and more 
cancers and other diseases have been thought to arise from infection with viruses, though 
not necessarily retroviruses, via oncogene capture and activation, and by direct infection. 
Finally, retroviruses are uniquely suited as viable gene therapy vectors.  Because 
retroviruses permanently insert a copy of their genetic material into the infected host 
genome, they are ideal candidates for gene delivery vehicles.  Retroviral vectors can be 
engineered to carry therapeutic genes to replace host cell deficiencies, or they may be 
modified to carry “suicide” genes that target cells such as virus-infected cells or cancer 
cells.  Such vectors have been used with success to treat Adenosine Deaminase (ADA) 
deficiency and Severe Combined Immune Deficiency (SCID) (4, 12).     
Life Cycle. The retroviridae are divided into 7 genera, largely based on sequence 
similarity of the pol gene.  All retroviruses are single-stranded RNA viruses that replicate 
through a DNA intermediate via an enzyme called reverse transcriptase.  HIV-1 is a 
member of the lentivirus genus. MLV and spleen necrosis virus (SNV) are members of 
the gammaretrovirus genus.  The three studies discussed in this work were carried out 
with either MLV- or SNV- based systems.  The life cycle of a retrovirus is shown in 
Figure 1. 
Retroviruses require the synthesis of a double-stranded DNA intermediate of their 
RNA genome to successfully complete their replication cycle.  A retrovirus first infects a 
cell by attaching to a surface receptor of a host cell and entering the cell either by direct 
fusion or endocytosis (Fig 1A).  In most retroviruses, reverse transcription occurs in the 
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cytoplasm of the infected host cell.  Reverse transcription is the process by which the 
viral enzyme reverse transcriptase (RT) copies the genomic viral RNA into a double-
stranded DNA (Fig 1B).  This viral DNA can integrate into the host genome to form a 
provirus.  Integration of the provirus into host cell DNA is mediated by the viral enzyme 
integrase (IN).  In HIV-1, this double-stranded DNA is imported to the nucleus and 
integrated into the genome of the host cell to form a provirus (Fig 1C).  Unlike HIV-1, 
the pre-integration complexes of SNV and MLV lack the ability to traverse the nuclear 
membrane; so therefore, MLV and SNV viral DNA can only integrate into the 
chromosomes of mitotically active cells because the nuclear membrane is dissolved 
temporarily during mitosis.  Once inserted, the cellular enzyme RNA Pol II can transcribe 
the provirus to make RNA transcripts, which are modified by cellular enzymes so each 
transcript contains 3’ poly-A tail and a 5’ cap (Fig 1D)(51).  Some of the viral RNA 
transcripts are spliced, and both the full-length viral RNA and spliced transcripts can be 
used as a template for translation to generate viral proteins.  The full-length viral RNA 
transcripts are specifically packaged into the virion.  The viral Gag polyproteins and viral 
RNA are transported the RNA to the membrane for virus assembly.  Viral proteins and 
two copies of viral RNA are assembled into a virion (Fig 1E), which are released from 
the cell surface by budding.   
Virus Genome Structure.  The process of reverse transcription requires that 
retroviruses possess a mechanism by which the viral RNA can be synthesized into a DNA 
copy.  The two forms of a retroviral genome, RNA and DNA, are shown in figure 2.  The 
terminal regions of the retrovirus RNA genome differ from that of the DNA form, and 
therefore reverse transcription of the RNA into DNA involves the duplication of the 
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terminal ends of the viral RNA in the DNA copy.  The viral sequence in the RNA 
transcript starts at the beginning of the 5’ R and concludes at the end of the 3’ R (Fig 2A).  
As a result there is one copy of the U3 at the 3’ end, one copy of U5 at the 5’ end, and 
two copies of R in the viral RNA.  During the process of reverse transcription, the U3 and 
U5 are duplicated to form the long terminal repeat (LTR) at both ends of the DNA 
genome (Fig 2B).  LTRs flank the internal part of the proviral genome and contain many 
cis-acting sequences necessary for viral replication, including a U3 region, a U5 region, 
an R region, and two attachment (att) sites, attL and attR.  The U3 contains promoter and 
enhancer sequences important for RNA transcription (22, 30).  The R plays a critical role 
in the minus-strand DNA transfer of reverse transcription, and may contain other 
regulatory sequences such as a transcription termination signal and cis-acting elements 
that enhance transcription (23). The att sites are recognized by the IN to specifically 
integrate the viral DNA into the host cell chromosome (9, 41).  The U5 region plays an 
important role in reverse transcription and carries the transcription termination signal for 
some retroviruses.  The region between the two LTRs  (Figure 3) also contains cis-acting 
sequences, such as the primer binding site (PBS), packaging or encapsidation signals 
(denoted Ψ for MLV and E for SNV), and the polypurine tract (PPT). Ψ and E are 
required for the incorporation of viral RNA into virions.  The PBS is the site of initiation 
of reverse transcription, and the PPT is the first site of initiation of plus-strand DNA 
synthesis. All retroviruses have at least four genes, termed gag, pro, pol, and env.  Gag 
(short for group-specific antigen) encodes the proteins that form the viral structures, pro 
(short for protease) encodes the viral protease, and pol encodes  RT, and IN.  Env 
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encodes the envelope glycoproteins, which mediate entry into the host cell during 
infection.   These proteins are further discussed below. 
Retroviruses as research tools.  Genetically modified retroviral systems can be 
used to study aspects of the retroviral life cycle.  A retroviral vector is a retrovirus that 
has had some or all of its protein-coding genes deleted so that only the cis-acting 
sequences remain intact, an aspect that is exploitable to develop a system for studying 
virus replication.  Replication of the viral RNA into DNA requires the cis-acting 
sequences discussed above, but can occur in the absence of the genes encoding the viral 
proteins.  The proteins necessary for viral replication can be provided in trans by 
“helper” constructs that express the viral enzymes and structural proteins (37).  A 
retroviral vector can be introduced into cells containing helper constructs; since the 
vector RNA contains the packaging signal the RNA will be specifically packaged by viral 
structural proteins to produce virus particles.  Produced viruses can infect permissive 
target cells, and the viral proteins in the virions can carry out reverse transcription and 
integration of the viral DNA.  However, viruses generated from the helper cells cannot 
replicate, because the vector RNA packaged into virions do not encode viral proteins; 
once integrated into the host these vectors cannot produce more infectious virions.  
Therefore vectors and helper cell lines make it possible to investigate retrovirus biology 
during one round of replication. 
Reverse Transcription.  The process of reverse transcription requires an 
uncharged cellular tRNA that codes for a specific amino acid to anneal to the PBS, which 
is located near the 5’ end of the retrovirus RNA (Figure 3).  RT uses the tRNA as a 
primer and synthesizes a DNA copy of the U5 and R that is termed minus-strand strong-
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stop DNA (Fig 3A).  A component of the RT, known as ribonuclease H (RNase H), 
degrades the viral RNA in RNA: DNA hybrids and leaves the minus-strand strong-stop 
DNA as single stranded DNA.  The R region of the single-stranded minus-strand strong-
stop DNA is complementary to the R region at the 3’ end of the viral RNA.  Using this 
complementarity, the minus-strand strong-stop DNA is transferred to the 3’ end of the 
retroviral RNA, an event termed minus-strand DNA transfer (Fig 3B).  Once this event 
occurs, minus-strand DNA synthesis can resume and start copying the RNA near the 3’ 
end of the retroviral genome.  Frequently during reverse transcription, RT can dissociate 
and re-associate from the template.  If the RT dissociates from the viral template while it 
is copying the 5’ R region into minus-strand DNA, only a portion of this R is copied into 
minus-strand DNA, and is termed minus-strand weak-stop DNA.  It is estimated that 
murine leukemia virus (MLV) and spleen necrosis virus (SNV) use minus-strand weak-
stop DNA to carry out minus-strand DNA transfer 10-20% of the time (34, 42) . 
Once minus-strand DNA synthesis proceeds past the PPT, RNase H makes a 
specific cleavage in this sequence, resistant to degradation by RNase H, which allows it 
to serve as the primer for the initiation of plus-strand DNA synthesis.    Plus-strand DNA 
synthesis occurs in a 5’-to-3’ direction, and copies the minus-strand DNA and 18 nt of 
the tRNA primer (47)(Fig 3C).   After the plus-strand DNA synthesis reaches the 5’ end 
of the minus-strand DNA, a second transfer step, termed plus-strand DNA transfer, must 
occur to complete reverse transcription.  Plus-strand DNA transfer is mediated by the 
complementarity between the PBS sequences in the minus-strand DNA and the 18 
nucleotides of the 3’ end of the tRNA that is complementary to the PBS, on the 5’ end of 
the minus-strand DNA.  This second DNA strand transfer event does not occur until the 
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plus-strand strong-stop DNA has been synthesized fully and the minus-strand DNA 
synthesis has proceeded through the PBS.  Most plus-strand DNA synthesis occurs in a 
continuous fashion, but in some retroviruses additional priming sites for plus-strand DNA 
synthesis allow for discontinuous synthesis of plus-strand DNA (43).  Once plus-strand 
DNA transfer has occurred, plus-strand DNA synthesis continues until the entire minus-
strand DNA is copied.  The result is a double-stranded DNA copy of the retrovirus 
genome, ready for insertion into the host cell’s genome (Fig 3D).   
Integration of Viral DNA.  IN carries out the insertion of the viral cDNA into 
the host genome to form the provirus.  Integration is a two-step process. The first step is 
to process the 3’OH on each end of the viral att sites in the cDNA, and the second step is 
a strand-transfer reaction that involves a nucleophilic attack of the 3’OH to the acceptor 
DNA in the cellular genome.  Following these two reactions, cellular ligases repair the 
nicks left in the viral-cellular DNA junction.  Selection of sites in the host genome for 
integration is not site-specific. However, there may be more preferred sites in the 
genome.  For example, areas where DNA is coiled around histones seem to be favored 
and not transcriptionally active DNA that is unwound, as was previously thought (50).  
Once integrated into the host genome, the provirus is permanently ensconced in the 
genetic material of the cell. 
Retroviral Assembly. Retroviral assembly is a complex process that requires an 
ordered interplay among viral proteins, viral RNA, and cellular components. Once a 
retrovirus has its DNA integrated into the infected cell, it must successfully transport 
transcripts of its RNA to the cytoplasm of the infected cell, synthesize its major structural 
proteins and enzymes, and transport these components to a designated location in the 
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infected cell so that a highly organized virus particle can form.  During virus assembly 
parameters such as virion size, content, and morphology must all be within narrow 
constraints for formation of viable virus particles.   The roles of many of these 
components of viral assembly are still being dissected.  
 Retroviral assembly is directed by the group-specific antigen gene (gag) that is 
both necessary and sufficient to direct assembly of virus-like particles in vitro (17).  In 
murine leukemia virus (MLV), the Gag polyproteins consist of four protein domains: 
matrix (MA), p12 (a protein of 12 kD in size), capsid (CA), and nucleocapsid (NC).  MA 
contains a myristolation signal, and is crucial for Gag targeting to the membrane of the 
infected cell for budding.   The p12 proteins contain a conserved late domain motif, 
PPPY, which is critical for release of the particle from the cell.  NC is a nucleic-acid 
binding protein that binds to viral RNA to stabilize it, and although NC has non-specific 
nucleic acid binding properties, it is responsible for the specific incorporation of viral 
genomic RNA into the virions (3, 5).  NC also has been shown to play a role in the 
processivity of reverse transcription (55), as well as in strand-transfer events.  CA is the 
major structural protein of retroviruses.  It forms the virus core, which encapsulates the 
viral enzymes and nucleic acid.  The Gag polyproteins are synthesized together as a large 
precursor protein and remain so throughout the assembly and budding process.  Shortly 
after virus release from the infected cell the Gag polyproteins are cleaved into their 
smaller components by the virus protease.  The protease is a domain of the larger Gag-
Pol precursor protein that contains the virus enzymes for reverse transcription, 
integration, and proteolytic processing.  With the exception of human foamy virus 
(HFV), the Pol polyproteins are always translated as part of a Gag-Pol precursor, at 
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roughly 10% the rate of the Gag polyproteins.  This Gag-Pol polyproteins are translated 
either by an in-frame suppression of a stop codon between the Gag and PR sequences in 
the mRNA, or by a –1 frame shift after the NC sequences (25, 46, 53, 54).  The Gag-Pol 
and Gag polyproteins associate together to form the budding virus particles. 
In MLV, the first step of assembly is trafficking the Gag and Gag-Pol 
polyproteins to the plasma membrane, from which they bud as immature virions.  Once at 
the membrane, the Gag and Gag-Pol proteins associate together in an organized fashion 
and begin their egress from the infected cell. During this process, viral RNA must be 
incorporated into the budding particle.  The genomic RNA acts as a structural scaffold on 
which the Gag and Gag-Pol molecules associate (38). Once the virus has completely 
budded from the cell, it is released from the outer surface.  Shortly after this, viral 
protease in the Gag-Pol cleaves all the polyproteins to their smaller components. 
Proteolytic processing leads to maturation of the virus core to make a virus that is capable 
of infecting another cell. In this process, several parameters are crucial: the specific 
incorporation of viral RNA, exclusion of cellular components, and maintenance of a well-
defined particle size and morphology. 
The maturation of viruses is evident by electron micrograph (EM) studies as a 
transition from a hollow-looking sphere to spheres that contain an electron-dense region 
in their centers (19).  Mature, infectious virus particles are typically 100 nm in diameter 
and contain a condensed virus core in the center.    
 CA has been studied in several different retroviruses, and a brief overview of 
what is known about this protein in different retroviruses is discussed below.  The role of 
the CA protein in retrovirus assembly is not clearly understood.  It is well known that the 
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CA protein forms the condensed cores of the mature virus particles, but mutational 
analyses of this protein indicate it plays a role in assembly as well.  CA proteins consist 
of two domains, an N-terminal domain (NTD) and a C-terminal domain (CTD).  Cross-
linking studies of the N terminal and C-terminal CA domains in HIV-1 revealed that both 
domains participate in CA dimerization (36) that is required for formation of the highly 
organized core structure.  HIV-1 CA has also been shown to bind human cyclophilin A 
(Cyp A) at its amino terminal end, possibly to help promote virus core disassembly 
following infection (20).  Mutational analyses of the NTD of HTLV-1 were found to be 
critical for particle production, while mutations in the CTD were not (44). 
In the central region of the CA protein is a universally conserved stretch of 20 
amino acids termed the Major Homology Region (MHR) (10). The structure of the MHR 
has been examined by nuclear resonance magnetic (NMR) spectroscopy and circular 
dichroism spectroscopy, and a helical structure to the MHR was proposed (6, 7).  Several 
roles for the MHR during virus assembly have been proposed.   Mutational analyses of 
the MHR in HIV-1 have suggested this region has a role in morphogenesis, and it has 
also been suggested that the MHR may be involved in CypA binding (8). In addition, 
mutation of the conserved residues of the MHR led to abolishment of viral replication 
and significant reduction of particle formation in vivo (35).  Lastly, the MHR may be 
involved in promoting ordered interactions between Gag and Gag-Pol molecules (48).  
CA association properties have been demonstrated to be pH dependent, suggesting that 
the milieu surrounding the CA proteins during assembly influences its oligomerization 
properties (16). 
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   CA proteins have also been recognized as a genetic determinant of size in Rous 
Sarcoma Virus (RSV) particles (28).  Specifically, a region of CA as well as the spacer 
peptide (SP) mediated the size of RSV particles.  Deletions of the CA-SP region resulted 
in low-density particles of various sizes.  Furthermore, it was also proposed that the SP of 
RSV Gag was involved in oligomerization and/or folding of the RSV CA subunits during 
assembly (11).  HIV-1 also contains a spacer peptide, p2, and mutations in the CA-p2 
region abrogated HIV-1 core formation (1, 27).  Furthermore, it was suggested that this 
CA-p2 region forms a putative alpha-helix structure critical for formation of mature virus 
cores (1).  Thus, two genetically distinct retroviruses, RSV and HIV-1, have been 
demonstrated to possess sequences in the C-terminal portion of CA that work in 
conjunction with a small peptide to ensure proper particle formation. 
 Few studies have looked at the C-terminal domain of CA in other retroviruses to 
investigate a possible role for this region in virus assembly.  Although some other 
retroviral families, such as the gammaretrovirus family, do not possess a spacer peptide 
between CA and NC like RSV and HIV-1, they must possess a mechanism by which they 
form mature particles.  It is possible that a region in the C-terminal end of CA or the N-
terminal end of NC also contributes the function of the spacer peptide in other 
retroviruses.  Extensive mutational analysis of murine leukemia virus (MLV) NC has 
been done, and this region does not seem to play a role in virus capsid formation, or in 
virus particle size determination. (45, 55-57).  However, there is a sequence at the end of 
MLV CA, which has not been characterized and could possibly play the same role as the 
CA-SP domain in RSV and the CA-p2 domain in HIV-1 in virus core formation.  In aim 
three, mutational analysis of this region will be discussed, as well as its impact on virus 
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assembly, morphology, and replication.  A structural model will be proposed to explain 
the impact of this region on MLV virus assembly. 
Viral Enzymes.    The PR domain of the Pol protein cleaves the individual viral 
proteins from their polyproteins precursors late in the assembly process.  The budding 
process is poorly understood, but it involves ordered Gag-Gag and Gag-GagPol 
interactions among the Gag and Gag-Pol precursor proteins to regulate the size and 
content of the new virions.  The budding and assembly process is regulated such that new 
virus particles are of a defined size (100 nm in diameter) and morphology (circular with a 
dense core).  
The products of the Pol gene, namely RT, RNase H (RH), and integrase (IN) are 
the main participants in reverse transcription and integration, respectively.  RT is a RNA-
and DNA-dependent DNA polymerase, and is required for polymerization during reverse 
transcription.  IN is the viral enzyme responsible for integration of viral DNA into the 
host cell, but it has also been shown to play a non-enzymatic role in reverse transcription 
in MLV and HIV-1 as well (29, 32, 52).    
The primary sequence of RT encodes its polymerase function in the amino 
terminal two-thirds and the RH function in the 3’ end (Figure 4).  It is possible to mutate 
the polymerase region of RT without affecting RH function, and vice versa.   
HIV-1 RT is found as a heterodimer solution, consisting as two subunits- a p51 
subunit and a p66 subunit (31).  The difference between the p51 and p66 subunit is that 
the p66 subunit contains the RH domain.  Although HIV-1 RT has two polymerase 
subunits, all enzymatic activity is located in the p66 subunit.  In contrast, it has been 
hypothesized that MLV RT is a monomer that dimerizes when presented with a template 
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(REF), and the oligomerization properties of SNV RT have not been published.  Crystal 
structures of HIV-1 RT show that the active p66 subunit is shaped like a right hand.  The 
domains of RT have been correspondingly called the “fingers”, “palm”, and “thumb” 
domains, and there is also a connecting region and the RNase H domain.  The palm 
domain contains the catalytic core of RT.  The catalytic core domain of RT contains three 
conserved aspartate residues, a triad required for polymerase activity.  Two of the three 
conserved aspartate residues are located in the YVDD motif common to all retroviral 
RTs.  The fingers form the template-primer grip, and the thumb helps to position the 
template as it proceeds through the RT complex.  The fingers and thumb of RT are 
thought to be flexible, a property that helps to position the template and primer in the 
enzyme complex. The RH domain of RT contains a catalytic core that binds metal ions 
for its enzymatic activity.  By itself, HIV-1 RNase H cannot bind its nucleic acid 
substrate; hence it requires physical association with the RT to be active in vivo. 
IN carries out the integration reaction to form the provirus during viral infection.  
Retroviral INs range from 280 to 450 amino acids in length and contain three conserved 
regions: an amino terminal HHCC motif, a catalytic core, and a less conserved carboxyl 
terminus.  The HHCC motif is thought to bind Zinc to form a zinc finger, the central 
catalytic core has a D,D(35)E motif (a conserved feature of endonucleases), and the 3’ 
end has DNA binding properties.  IN proteins must oligomerimerize on each end of the 
virus cDNA to carry out these steps; therefore a minimum of four IN molecules per 
infectious event are needed to integrate one viral DNA.   
Biological Impact of Reverse Transcription.  The process of reverse 
transcription is important to retrovirus biology in many ways.  RT has a low affinity for 
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the viral template during viral DNA synthesis compared with eukaryotic polymerases, 
rendering the enzyme likely to dissociate from the template frequently during 
polymerization.  Low affinity leads to the high recombination rates previously measured 
in retroviruses and contributes to retroviral evolution.  Mutations and recombinations 
occurring during reverse transcription generate viral variants that increase host immune 
system evasion and resistance to antiviral therapy.  Vaccines designed to prevent or treat 
HIV-1 infection will have to confer protection from a diverse population of viruses.  
Increased viral diversity also poses a treatment problem, as HIV-1 is able to acquire 
resistance to chemotherapeutic agents.  Therefore, understanding the mechanisms of 
reverse transcription and recombination may have direct implications for management of 
the global AIDS epidemic.  In addition, retroviral vectors have been used in gene therapy 
trials to treat human diseases. Understanding reverse transcription and recombination can 
help develop better and safer vectors for gene delivery.  Additionally, new targets are also 
needed for antiretroviral therapy; possible targets could be developed to disrupt viral 
assembly.    
Aim 1. In MLV, the R region is primarily involved in the minus-strand DNA 
transfer reaction, and conflicting reports have tested whether the transfer reaction is 
driven by specific RNA sequences in the RNA or by the sequence homology between the 
two R regions.  Some labs have shown that other viruses’ R sequences can mediate 
minus-strand DNA transfers while mediation of minus-strand DNA transfers by non-viral 
sequences was not detected (2).   Substitution of different virus R sequences suggests that 
homology plays a role in minus-strand DNA transfer. 
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In the first chapter, the importance of the ‘R’ sequence context on reverse 
transcription was investigated. Specifically, a set of retroviral vectors containing non-
viral sequences in their LTRs was constructed to see if these sequences could be used 
instead of the native viral R sequence to mediate minus-strand DNA transfer. 
Furthermore, these sequences were engineered such that their use for minus-strand DNA 
transfer would result in functional reconstitution and activation of a gene in the provirus. 
By providing alternate sequences for homology during minus-strand transfer we 
directly determined the requirement of sequence in the R region.  The R region’s role in 
minus-strand transfer could either be through the homology contained in the two copies 
of the R region or by specific sequences in the R region.  We proposed that the 
mechanisms by which the R region mediated minus-strand DNA transfer was through the 
homology it provides between the 5’ and 3’ end of the viral genome, and not from 
specific sequences contained in the R region.  If this was true, then alternate sequences 
could be inserted into the LTRs of a retroviral vector and homology between these 
regions would mediate minus-strand DNA transfer.   Homology plays a role in other 
template-switching events in reverse transcription.  Direct repeat deletion is a mechanism 
by which the RT dissociates from the RNA template during reverse transcription and re-
associates with the template at a different place that contains sequence identity to the 
newly synthesized DNA.  The result is that all the intervening sequences between the 
points of disassociation and re-association are deleted from the transcribed DNA.  This 
phenomenon has been successfully exploited to reconstitute functional genes in vivo and 
a model has been proposed to explain it (15).  Retrovirus vectors that contained directly 
repeated sequences underwent deletion at a high rate (>90%), a process called direct 
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repeat deletion.  The sequences of the direct repeat did not appear to be important, as 
several different sequences have been used to demonstrate this phenomenon.  Unless RT 
has different properties when copying the R region of the RNA, it is reasonable to 
propose that nonviral sequences of homology could mediate minus-strand DNA transfer 
as well as the native viral R region.  Some labs have suggested that R regions cannot be 
substituted, but these reports were generated from in vitro systems that only roughly 
approximate conditions in viruses (2).  Recently, it was shown that R sequences could 
mediate minus-strand DNA transfer even when they are incomplete, with as little as 12 nt 
in length (14).  Furthermore, if non-viral sequences could mediate minus-strand DNA 
transfer, sequences could be inserted into the viral vector such that successful minus-
strand DNA transfer using the non-viral sequence would reconstitute a functional gene in 
the LTR of the provirus.  This would be a novel strategy for a self-activating gene 
therapy vector. 
Aim 2. The highly flexible nature of retroviruses suggests that two species of 
retroviruses could interact.  If a single cell were infected with two different retroviruses, 
there is a potential that the Gag and Gag-Pol transcripts could interact and form a 
phenotypically mixed virus.  Normally, this would not happen because the Gag 
polyproteins are the necessary and sufficient element for virus particle production, and it 
has been suggested that two different species of Gag, particularly of MLV and SNV, 
cannot co-assemble to form infectious viruses (Beasley and Hu, unpublished data).  
However, since Pol proteins are always expressed in the context of a Gag-Pol fusion 
protein (with the exception of HFV), it is not known if different species of Pol could be 
assembled into the same virus particle.  A chimeric Gag-Pol expression vector could be 
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used to determine if this mixing of Pol species into the virus were possible.  If it were 
possible and two different species of Pol could co-assemble into the same virion this 
would expose another mechanism by which two different species of retrovirus Pol could 
interact to increase viral diversity. 
In order to determine whether different species of Pol can interact and co-
assemble into the same virus particle, a system that makes it possible to determine 
whether two different species of Pol are in the virus must be designed.  The best way to 
devise such a system would be trans-complementation, which has been a powerful tool 
for dissecting the roles of the individual Pol proteins in the retrovirus (24).  To 
successfully utilize a trans-complementation system to determine co-packaging properties 
of different Pols, mutations were introduced into the Pol domains of an SNV Gag-Pol and 
an SNV Gag-MLV Pol expression vectors.  A cell line was constructed that stably 
expressed both species of Pol, and viruses produced from this cell line were tested to see 
if they contained both species of Pol. 
More recently, evidence has been provided that RT and IN are both necessary for 
efficient reverse transcription.  HIV-1 IN could be provided in trans by a Vpr-IN fusion 
protein to rescue the virus carrying the IN mutations that disrupted the HHCC domain.  
HIV-1 vectors containing various mutations that disrupted the HHCC domain were 
unable to synthesize early (minus-strand strong-stop), intermediate (U3-U5), or late (R-
gag) minus-strand DNA. However, early and late viral DNA synthesis could be rescued 
by providing IN in trans (52).  In addition, only Vpr fused with HIV-1 IN was able to 
effectively rescue viral DNA synthesis.  Vpr fused with HIV-2 IN only increased viral 
DNA synthesis 2-3 fold compared to IN mutants alone, although HIV-2 IN increased 
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integration frequency almost 100-fold, indicating that HIV-2 IN was in the virus particles 
and reverse transcription complex.  This study indicated that IN was critical for 
successful reverse transcription in HIV-1 and that there was a direct physical interaction 
between the RT and IN.  Furthermore, the roles of IN were somewhat species specific- 
HIV-1 IN could rescue reverse transcription and integration, but HIV-2 IN could only 
rescue integration.  A similar approach was used to establish an IN role in reverse 
transcription for MLV.  A Gag∆NC-IN fusion protein was constructed to provide IN to 
MLV viruses in trans.  It was found that without the functional IN provided from the 
Gag∆NC-IN, reverse transcription in viruses carrying deletions of partial deletions of IN 
certain mutant forms of MLV IN was not detectable.  Once the Gag∆NC-IN fusion 
construct was introduced, reverse transcription was restored to wild type levels.  
Specifically, the C-terminal thirty-four amino acids of MLV IN was found to be crucial 
for reverse transcription in this study (29). 
In the second chapter, the functional complementation of RT and IN proteins 
from two distantly related simple retroviruses was examined.  Specifically, whether 
heterologous RT and IN from spleen necrosis virus (SNV) and MLV could complement 
each other in vivo was investigated in order to establish whether two species of Pol could 
co-assemble into the same virion.  Trans-complementation is a powerful tool for 
dissecting the individual contributions of different retroviral proteins to the virus life 
cycle. Although RT alone can reverse transcribe RNA into DNA in a test tube, current 
studies indicated that more proteins were involved in the viral DNA synthesis in vivo.  
The second chapter investigated whether RT and IN from distantly related viruses could 
functionally complement each other.  This provided insight into the mechanisms of 
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interaction between these two enzymes.  Furthermore, this also delineated the interactions 
between distantly related retroviruses. Pol mutants in SNV and MLV Pol were 
constructed and used to establish a trans-complementation system for studying mutations 
in IN and RT and their effects on reverse transcription and integration. 
Aim 3. Retroviral assembly is a complex process and many insights still are 
needed before it can be properly understood.  During the assembly process, a retrovirus 
must regulate its size, contents and morphology within narrow constraints to ensure virus 
viability.  It is known that Gag is sufficient for particle formation and release, and that 
individual protein components each have specific roles in particle assembly.  Some 
retroviruses, such as Rous Sarcoma Virus (RSV) and HIV-1, encode proteins between 
CA and NC that are short peptides, the spacer peptide (SP) for RSV, and p2 for HIV-1.    
The spacer peptide and the p2 domain were found to be critical for proper assembly in 
RSV and HIV-1.  Specifically, the spacer peptide and p2 each worked with CA protein to 
form the proper particle size and morphology.  Even though not all retroviruses encode 
short peptides between the CA and NC to carry out this function, it was reasoned that 
they must have a mechanism by which they carry out these assembly functions.  It was 
hypothesized that gammaretroviruses utilized a distinct motif at the 3’ end of the CA 
domain to carry out this function. 
In the third chapter, mechanisms of retrovirus assembly were studied, specifically 
the contribution of a unique motif in the 3’ end of MLV CA to virus assembly.  This 
novel motif has been observed in several gammaretroviruses, and its role in 
gammaretrovirus assembly has not been explored.  Additionally, the role of CA as a 
structural protein in retroviruses has been well established, but its role in the assembly 
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process is not well understood.  The impact of this domain on the budding and assembly 
process was investigated, particularly whether it contributed the same function to 
assembly in MLV as the spacer peptide in RSV and p2 in HIV-1.  Several deletion 
mutants of this region were constructed and tested to determine the features of this motif 
that are required for its function, including its role in virus size determination, content, 
and morphology.  
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FIGURE LEGENDS 
Figure 1: Life Cycle of a retrovirus.  Red circles denote enzymes used in reverse 
transcription and viral transcription.  The yellow circle represents the cytoplasm of the 
infected cell.  The blue circle is the nucleus.  The wavy lines indicate cellular 
chromosomes.  Blue and red rectangles represent the LTRs during replication. 
 
Figure 2: Two nucleic acid forms of retroviral genomes.  RNA is denoted with a dotted 
line, DNA with a heavy solid line.  AttL, left attachment site, attR, right attachmet site.   
 
Figure 3: The steps of reverse transcription.  RNA is denoted as a thin dark line.  Minus-
strand DNA is denoted as a dotted line.  Plus-strand DNA is a thick solid line. 
 
Figure 4:  Structure of Retroviral Pol gene, with crystal structure of HIV-1 RT.  From 
Retroviruses, edited by J.M. Coffin, et al. 
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Figure 2.  Nucleic Acid Structure of Retroviral Genomes 
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Figure 1. Retroviral Life Cycle. From Retroviruses, Coffin et al. 
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Figure 3.  Reverse Transcription. From Retroviruses, Coffin et al. 
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Figure 4.  HIV-1 Reverse Transcriptase.  From Retroviruses, Coffin et al. 
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ABSTRACT 
 
 Minus-strand DNA transfer, an essential step in retroviral reverse transcription, is 
mediated by the two repeat (R) regions in the viral genome.  It is unclear whether R 
simply serves as a homologous sequence to mediate the strand transfer or contains 
specific sequences to promote strand transfer.  To test the hypothesis that the molecular 
mechanism by which R mediates strand transfer is based on homology rather than 
specific sequences, we examined whether nonviral sequences can be used to facilitate 
minus-strand DNA transfer.  The green fluorescent protein gene (GFP) was divided into 
two fragments, GF and FP, containing the 5´ and 3´ portions of GFP, respectively.  An 
overlap of 85 bp of homology, designated F, existed between GF and FP.  A murine 
leukemia virus-based vector was modified by insertion of the FP and GF fragments into 
the 5´ and 3´ long terminal repeats, respectively.  Viral RNA generated from this vector 
contained FP-R at the 5´ end and GF-R near the 3´ end.  Utilization of the F fragment to 
mediate minus-strand DNA transfer was expected to reconstitute GFP during reverse 
transcription.  Flow cytometry analyses demonstrated that GFP was expressed in 73 to 
92% of the infected cells, depending on the structure of the viral construct.  This 
indicated that GFP was reconstituted at a high frequency; molecular characterization 
further confirmed the accurate reconstitution of GFP.  These data indicated that nonviral 
sequences could be used to efficiently mediate minus-strand DNA transfer.  Therefore, 
placement and homology, not specific sequence context, are the important elements in R 
for minus-strand DNA transfer.   In addition, these experiments demonstrate that minus-
strand DNA transfer can be used to efficiently reconstitute genes for gene therapy 
applications.   
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INTRODUCTION 
 
All retroviruses replicate their genome using an RNA form to generate a DNA 
form in a process called reverse transcription (43).  The viral RNA is characterized by 
short repeat (R) regions at the 5´ and 3´ ends (7, 15).  The R region at the 5´ end is 
immediately followed by a unique 5´ sequence named U5.  Because the viral RNA is the 
mRNA or the plus strand, the first strand of DNA synthesized is complementary to the 
viral RNA and is referred to as the minus-strand DNA.  Viral DNA synthesis initiates 
near the 5´ end of the viral RNA, using a tRNA primer that binds to the primer-binding 
site (PBS) in the viral RNA (7).  Reverse transcriptase (RT) copies R and U5 and quickly 
reaches the 5´ end of the RNA template.  This short stretch of DNA that contains R and 
U5 is referred to as minus-strand strong-stop DNA.  It is thought that the RNase H 
activity of RT degrades the RNA template in the RNA/DNA hybrid and exposes the 
strong-stop DNA.  The newly synthesized R in the viral DNA is complementary to the R 
near the 3´ end of the viral RNA.  Presumably, the complementarity facilitates alignment 
and hybridization of the two nucleic acids and allows RT to continue DNA synthesis, 
using sequences near the 3´ end of the viral RNA as a template.  This switching of the 
RT-complex from the 5´ end to near the 3´ end of the viral RNA, known as minus-strand 
DNA transfer, is an essential step in reverse trasncription (7, 15).  Minus-strand DNA 
transfer is primarily mediated by the strong-stop DNA (7, 15);  however, it has been 
observed that DNA containing U5 and only a portion of R, referred to as minus-strand 
weak-stop DNA, can also mediate minus-strand DNA transfer, although at a lower 
frequency (28, 29, 37, 45).   
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Minus-strand DNA transfer is accomplished through complex interactions 
between the viral proteins and nucleic acids.  At least two viral proteins, RT and 
nucleocapsid (NC), play important roles in this transfer.  The RNase H activity of RT is 
essential for minus-strand DNA transfer (5, 30, 35).  Through various in vitro assays, NC 
was also clearly demonstrated to facilitate the efficiency of minus-strand DNA transfer 
(2, 9, 13, 17, 21, 26, 34, 36, 39, 40, 44, 46).  
 Less is known about the requirement of cis-acting sequences for minus-strand 
DNA transfer.  The R regions vary significantly in length and sequence among different 
viruses.  The length of R can vary up to 25-fold (from the shortest R, 12 nt, in mouse 
mammary tumor virus to the longest R, 249 nt, in human T cell leukemia virus type II) 
(4, 7).  Furthermore, it was shown that in some viruses, such as murine leukemia virus 
(MLV), spleen necrosis virus, and human immunodeficiency virus type 1 (HIV-1), only a 
portion of R is needed to mediate minus-strand DNA transfer, because weak-stop DNA 
transfer events were observed (27-29, 37, 45).  In a recent study using a viral vector-cell 
culture system, we defined the relationship between the length of homology and the 
efficiency of minus-strand DNA transfer (8).  We found that 12 nt of homology is 
sufficient to mediate efficient minus-strand DNA transfer.   
Although homology length can play a role in the efficiency of minus-strand 
transfer, it was not clear whether there is a requirement for specific sequences in the R 
region for this transfer.  The R regions of various retroviruses do not have apparent 
conserved motifs.   However, in an in vitro assay using purified proteins and RNA, it was 
demonstrated that R sequences from MLV, Rous sarcoma virus, and HIV-1 could 
mediate minus-strand transfer, whereas a nonviral sequence failed to mediate strand 
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transfer (3).  This finding led to the hypothesis that the sequence context in the viral R 
region promotes strand transfer and viral sequences are required for efficient minus-
strand DNA transfer.     
Recent data from our laboratory indicated that efficient minus-strand DNA 
transfer can be mediated by short stretches of homology (8, 45). Therefore, we 
hypothesized that homology in the R region, rather than sequence context, is key to 
promoting this transfer.  To test this hypothesis, we examined whether nonviral 
sequences can mediate efficient minus-strand DNA transfer. 
 
MATERIALS AND METHODS 
    
Construction of vectors.  Plasmids pSR2-2GFP, pSR5-FP-GF, pSR6-2wtLTR, 
and pMS2-FP-GF-no3R were derived from pAR2 (45), an MLV-based vector that 
contains the hygromycin phosphotransferase B gene (hygro) (16).  For the nomenclature 
used here, plasmid names begin with p, whereas the names of viruses derived from the 
plasmids do not (e.g., pSR5-FP-GF refers to the plasmid construct; SR5-FP-GF refers to 
the virus derived from this plasmid).   
pAR2 was digested to completion with AatII and self-ligated to generate pTR1, a 
plasmid that contained a portion of hygro and the downstream long terminal repeat 
(LTR).  The green fluorescent protein gene (GFP) (6) from pGreen-Lantern-1 (Gibco) 
was amplified by PCR using primers GFPp1-AscI and PFG2p-csA.  Sequences of the 
primers are shown in Table 1.  The resulting DNA was digested with AscI and inserted 
into the AscI site between U3 and R in the upstream LTR of pAR2 to generate pCM1.  
GFP was amplified by PCR using primers GFPp3-EheI and PFG4p-ehEI; the amplified 
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product was digested with EheI and inserted into the EheI site between U3 and R in the 
pTR1 LTR to generate pCM2.  pCM1 and pCM2 were digested with ScaI, and the pCM1 
DNA fragment containing the upstream LTR with GFP was ligated to the pCM2 DNA 
fragment containing the downstream LTR.  The resulting plasmid, pSR1, contained 
hygro, and both LTRs had one copy of GFP.  pSR1 was digested with BstEII and ClaI to 
excise hygro, which was  replaced with the SV40 promoter-hygro fragment from pMSM2 
to generate pSR2-2GFP. 
The portion of GFP containing the 3´ 462-bp fragment, termed FP, was amplified 
by PCR using primers FPAscp1 and PFG2-pcsA (Table 1).  The PCR product was 
digested with AscI and inserted into the AscI site in the 5´ LTR of pAR2 to generate 
pTR4.  The portion of GFP containing the 5´ 350-bp fragment, termed GF, was amplified 
using primers FG-ehE-4p and GFPp3-EheI (Table 1).  The PCR product was digested 
with EheI and inserted into the EheI site of pTR1 to generate pTR3.  The pTR4 DNA 
fragment containing the upstream LTR with FP was isolated and the DNA fragment 
containing the downstream LTR with GF was isolated from pTR3.  These two DNA 
fragments were ligated to form pTR5.  pTR5 was digested with BstEII and ClaI  to excise 
hygro, which was replaced with the 1.7-kb  DNA fragment containing SV40 promoter-
hygro to generate pSR3.  DNA sequencing of pSR3 revealed the presence of an 
inactivating mutation in GF (data not shown).  To remove this mutation from the plasmid, 
pCM2 was digested with ClaI and MscI to excise the 3´ hygro, U3, and GF fragments, 
which were then ligated into the eluted 6.1-kb backbone of pSR3 that was generated by 
digestion with ClaI and partial digestion with MscI.  In the resulting plasmid, pSR5-FP-
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GF, the GF region contained the 5´ 350-bp of GFP and the FP region contaiedn the 3´ 
462-bp of GFP with a 85-bp F region shared by both GF and FP fragments. 
pSR6-2wtLTR was generated by replacing the 1.4-kb ClaI-BstEII fragment of 
pAR2 between the Ψ packaging signal and the 3´ end of hygro with the 1.7-kb BstEII-
ClaI fragment containing SV40-hygro from pMSM2.   
pJD220SVhy (14) was digested with ClaI and BstZ17I to isolate a 409-bp DNA 
fragment containing the SV40 termination signal.  pCM2 was digested with BstBI and 
BstZ17I to delete the 3´ 351-bp fragment containing a portion of GFP, R, and U5, then 
was treated with the Klenow fragment of Escherichia coli DNA polymerase I and ligated 
with the 409-bp ClaI-BstZ17I DNA fragment from JD220SVhy.  The resulting plasmid, 
pMS1, was digested with ScaI, and the fragment containing the 3´ LTR was isolated and 
ligated to ScaI-digested pSR5-FP-GF to generate pMS2-FP-GF-no3R.  pMP1 was 
derived from pWH390 (10) by the insertion of GFP upstream of the internal ribosomal 
entry site (IRES) from encephalomyocarditis virus (22, 23).  
Standard cloning techniques were used to construct all of the vectors (31).  
Plasmid structures were analyzed by restriction enzyme mapping.  All PCR-amplified 
DNA fragments that were cloned into plasmids were further analyzed by DNA 
sequencing to detect inadvertent mutations generated during the PCR procedures.      
Cell culture, DNA transfection, and virus infection.  PG13 cells  (American 
Type Culture Collection) were derived from NIH3T3 cells expressing MLV gag-pol and 
gibbon ape leukemia virus (GaLV) env (32).  D17 (American Type Culture Collection) is 
a dog osteosarcoma cell line permissive for MLV infection(38).  PG13 and D17 cells 
were maintained at 37oC in Dulbecco’s modified Eagle’s medium supplemented with 
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penicillin (50 U/ml; Gibco), streptomycin (50 µg/ml; Gibco), and bovine calf serum (10% 
for PG13 and 6% for D17). G418, a neomycin analog, was used for selection at a final 
concentration of 600 µg/ml for PG13 cells and 400 µg/ml for D17 cells.  Hygromycin 
was used at a final concentration of 300 µg/ml in PG13 cells and 120 µg/ml in D17 cells.    
 Transfections were performed using the calcium phosphate precipitation method 
as previously described (31) or TransfastTM transfection reagents from Promega as 
recommended by the manufacturer.  PG13 cells were plated at a density of 1 × 105 cells 
per 60-mm-diameter dish; 5 or 10 µg of vector DNA was used per dish for the 
TransfastTM or calcium phosphate transfection, respectively.  Transfected cells were 
placed on the appropriate drug selection; drug-resistant colonies were pooled, expanded, 
and plated at a density of 5 × 106 cells per 100-mm-diameter dish.  Virus was harvested 
from each transfected cell pool 48 h later and centrifuged at 3000 × g for 10 min to 
remove cellular debris.  Serial dilutions of the supernatants were used to infect D17 cells 
that were plated at 2 × 105 cells per 60-mm dish.  Infected D17 cells were then placed on 
appropriate drug selection.  Viral titers were calculated based on the number of drug-
resistant colonies and standardized to RT activities.  
RT assay.  A portion of the virus harvested from transfected PG13 cells was 
subjected to RT assays as previously described (18).  Briefly, harvested virus was 
centrifuged in a SW 28 rotor (Beckman) or a Surespin 630 rotor (Sorvall) at 25,000 rpm 
for 90 min.  Viral pellets were resuspended in serum-free medium and stored at –80oC.  
Exogenous RT activities were determined by incubating 10 µl of virus with 50 µg/ml οf 
20-mer oligo T (Integrated DNA Technologies), 100 µg/ml of poly(A) (Pharmacia), 60 
mM NaCl, 50 mM Tris (pH 8.0), 1 U/µl RNase inhibitor, 10 mM dithiothreitol, 0.6 mM 
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MnCl2, 80 µM dTTP, 0.5% IGE Pal (Sigma), and 10 µCi of [3H]dTTP (72 Ci/mmol, 
ICN).  The samples were incubated at 37oC for 90 min. The reaction mixtures were 
precipitated with 10% trichloroacetic acid (Sigma) and filtered through 0.45-µm-pore-
diamter Metricel membranes (Gelman Sciences, Inc.); the amount of [3H] incorporated 
was determined using a scintillation counter. 
Detection of GFP expression by flow cytometry and fluorescence microscopy.    
The number of cells in the transfected pools that expressed GFP was measured using flow 
cytometry (FACScan, Becton Dickinson); results were analyzed using CellQuest 
software (Becton Dickinson).  GFP expression in infected, drug-resistant D17 cells was 
analyzed by two methods.  Drug-resistant cell colonies from plates containing100, 10-1, 
and 10-2 viral dilutions were separately pooled for flow cytometry analyses.  Drug-
resistant colonies from 10-3, 10-4, and 10-5 viral dilution plates were analyzed by 
fluorescence microscopy (Axiovert inverted fluorescence microscope, Zeiss).  GFP 
expression in individual cell clones was also analyzed by flow cytometry and 
microscopy.   
Analyses of proviral structure by PCR and DNA sequencing.  Hygromycin-
resistant cell clones were isolated and lysed for use as PCR substrates.  The upstream 
LTR of the proviruses was amplified using primers in the U3  (MLVU3) and 5´ Ψ 
regions (ispVLM5´) (Table 1).  PCR products were analyzed by DNA sequencing with an 
automated sequencer (PE Biosystem) using one or more of the following primers: 
GF101, 5UVLM, R/3UM-629, PFG695, and PFG464 (Table 1).  
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RESULTS 
 
Vectors used to determine the primary sequence requirement for minus-
strand DNA transfer.  A series of MLV-based retroviral vectors was used to test the 
hypothesis that nonviral sequences can mediate minus-strand DNA transfer and that this 
process can reconstitute genes; the structure of these vectors are shown in Fig. 1A.  All of 
these vectors contained the cis-acting sequences necessary for retroviral replication, such 
as the PBS, packaging signal (Ψ+) , polypurine tract, and attachment sites.  In addition, 
most of gag- and the entire pol- and env-coding regions were deleted from these vectors.  
pSR2-2GFP, pSR5-FP-GF, pSR6-2wtLTR, and pMS2-FP-GF-no3R each contained an 
SV40 promoter upstream of hygro between the two LTRs.  pSR6-2wtLTR contained two 
unmodified LTRs, whereas pSR2-2GFP had two modified LTRs, each containing the 
full-length GFP between U3 and R.  pSR5-FP-GF also had two modified LTRs; the 
upstream LTR contained the 3´ 462-bp FP fragment of GFP between U3 and R, whereas 
the downstream LTR contained the 5´ 350-bp GF fragment of GFP between U3 and R.  
FP and GF share a homology stretch of 85 bp (the F region).  pMS2-FP-GF-no3R also 
had two modified LTRs similar to those in pSR5-FP-GF, except that the R and U5 
regions in the downstream LTR were replaced by a DNA fragment containing the SV40 
termination signal.  pMP1 contained two unmodified LTRs with GFP, IRES, and the 
neomycin phosphotransferase gene (neo) (24) between the LTRs. 
 pSR6-2wtLTR and pMP1 contained unmodified LTRs and were expected to 
produce RNAs with R at the two ends of the viral sequences that could mediate minus-
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strand DNA transfer.  The LTRs in pSR5-FP-GF were modified; as a result, the viral 
RNA produced was expected to contain FP-R-U5 at the 5´ end and U3-GF-R at the 3´ 
end of the viral sequences (Fig. 1B).  During reverse transcription, DNA synthesis was 
expected to copy U5, R, and FP to form minus-strand strong-stop DNA (Fig. 1B).  We 
hypothesized that if nonviral sequences can mediate minus-strand DNA strand transfer, 
then the 85-nt F region in the strong-stop DNA can hybridize to the F region at the 3´ end 
of viral RNA, reverse transcription can continue to copy the G region of the RNA, and 
GFP can be reconstituted.  On the other hand, if nonviral sequences cannot mediate 
minus-strand DNA transfer, then GFP cannot be reconstituted.  It is also known that at a 
lower frequency (~1-10%), minus-strand DNA synthesis terminates early to form weak-
stop DNA (28, 29, 37, 45).  These weak-stop DNAs might contain only U5 and R and 
would be expected to transfer to the 3´ end of viral RNA and form viral DNA containing 
GF between U3 and R.  Therefore, minus-strand transfer of these weak-stop DNAs was 
not expected to reconstitute GFP.   
The LTRs in pMS2-FP-GF-no3R were modified in a manner similar to those in 
pSR5-FP-GF except that R and U5 were deleted from the 3´ LTR.  The MS2-FP-GF-
no3R viral RNA was also expected to have FP-R at the 5´ end and U3-GF at the 3´ end of 
the viral sequences; however, the viral RNA did not contain R at the 3´ end.  If the F 
region could mediate minus-strand DNA transfer, then the strong-stop DNA would 
transfer to the 3´ end of the viral RNA sequence.  However, unlike SR5-FP-GF, the 
weak-stop DNA containing only U5 and R was not complementary to the sequences at 
the 3´ end of the viral RNA and should not be able to transfer efficiently.  Therefore, if 
the F region could not mediate efficient minus-strand DNA transfer, it was expected that 
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MS2-FP-GF-no3R would not be able to replicate well and would have a severely reduced 
viral titer.   
Each LTR in pSR2-2GFP contained a copy of GFP between U3 and R.  The RNA 
produced from these constructs was expected to contain GFP-R-U5 at the 5´ end and U3-
GFP-R at the 3´ end of the viral sequences.  Regardless of whether the virus used the R 
region or the nonviral sequences to mediate minus-strand DNA transfers, the resulting 
viral DNA would have LTRs with GFP between the U3 and R sequences.     
 Experimental protocol.  The outline of the experimental protocol is shown in 
Fig. 2.  These vectors were separately transfected into PG13 helper cells that expressed 
MLV gag-pol and GaLV env.  Transfected cells were subjected to appropriate drug 
selection, and resistant cell colonies were pooled.  All of the pools contained at least 250 
colonies.  Viruses were harvested from these pools; for each sample, a portion of the 
virus was used to measure the RT activity and another portion was serially diluted and 
used to infect D17 cells.  After the infected D17 cells were subjected to appropriate drug 
selection, the numbers of drug-resistant colonies were determined and were used to 
calculate the viral titers generated by these vectors.  Within each set of experiments, viral 
titers were standardized to the RT activities.  GFP expression from these drug-resistant 
colonies was analyzed by flow cytometry or fluorescence microscopy.  Infected, drug-
resistant D17 cell clones were isolated; GFP expression of these cell clones was 
determined by flow cytometry and fluorescence microscopy.  To examine the molecular 
nature of the minus-strand DNA transfer, a portion of the proviruses containing minus-
strand DNA transfer junctions was amplified from the infected cell clones by PCR and 
characterized by DNA sequencing.   
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 In this system, viral titers and minus-strand DNA transfers were examined in a 
single viral replication cycle, from the viruses produced in the PG13 cells to the 
proviruses generated in the D17 cells.  Viruses produced from the murine-derived PG13 
cells contained GaLV Env, which could not efficiently infect murine cells (32).  
Therefore, reinfection had little opportunity to occur in PG13 cells.  D17 target cells did 
not express gag-pol and env needed to produce virions containing these vectors to go 
through another round of viral replication.  Therefore, only one round of retroviral 
replication was allowed in this system.     
 Viral titers after one round of retroviral replication.   The titers for vectors 
MP1, SR2-2GFP, SR5-FP-GF, SR6-2wtLTR, and MS2-FP-GF-no3R are listed in Table 
2.  These titers were standardized to the RT activities.  The SR6-2wtLTR titer varied 
between 8.3 and 130 × 104 CFU/ml.  The SR5-FP-GF titer varied between 1.0 and 24 × 
104 CFU/ml.  The average difference between the SR6-2wtLTR titers and SR5-FP-GF 
titers was 6.8-fold.  The reductions in viral titers could have been caused by inserting 
sequences in the R region, similar to the 6- to 8-fold decreases in titers previously 
observed by another laboratory (1).  Alternatively, it was possible that the F region could 
not mediate the minus-strand DNA transfer and caused the decrease in the viral titer.  
This would suggest that most of the strong-stop DNA could not perform strand transfer 
and did not produce viral DNA capable of integrating into the host genome.  Most of the 
viral titer would be generated from viral DNA produced by the transfer of minus-strand 
weak-stop DNA.  Because the weak-stop DNA was expected to be generated at a 
frequency of ~1-10% (28, 29, 37, 45), we could not rule out the possibility that the 6.8-
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fold decrease in viral titers was caused by the inability of the strong-stop DNA to perform 
minus-strand DNA transfer.     
The SR2-2GFP and MS2-FP-GF-no3R titers varied from 4.1 to 14 × 104 CFU/ml 
and 1.3 to 21 × 104 CFU/ml, respectively.  There was no significant difference among the 
SR2-2GFP, SR5-FP-GF, and MS2-FP-GF-no3R titers (Two sample T test; P>0.8 for 
SR5-FP-GF and MS2-FP-GF-no3R, P>0.9 for SR5-FP-GF and SR2-2GFP).  MS2-FP-
GF-no3R RNA only contained the 5´ R and thus could not use R to mediate minus-strand 
DNA transfer.  Therefore, in order for MS2-FP-GF-no3R to generate viral titers similar 
to those of SR2-2GFP and SR5-FP-GF, the F region had to be able to mediate minus-
strand DNA transfer.  The proviruses generated by F region-mediated transfer would 
have reconstituted GFP, which could be confirmed by GFP expression or structural 
analyses.    
GF and FP fragments cannot confer positive GFP expression.  GFP 
expression in all of the transfected PG13 helper cell pools was examined by flow 
cytometry analyses.  As expected, pMP1- or pSR2-2GFP-transfected, drug-resistant cell 
pools contained significant numbers of GFP-expressing cells, generally between 45 and 
70%.  As expected, cell pools transfected with pSR6-2wtLTR did not contain a 
significant percentage of fluorescent cells (<2%), since these plasmids lacked GFP.  Cell 
pools transfected with pSR5-FP-GF or pMS2-FP-GF-no3R also did not contain a 
significant percentage of fluorescent cells (<2%), indicating that neither FP nor GF could 
express functional fluorescent proteins.         
GFP expression of infected cells.  Flow cytometry analyses were also performed 
on D17 cells infected with virus produced by different transfected cell pools.  Drug-
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resistant D17 cells were pooled and analyzed by flow cytometry; a representative set of 
flow cytometry analyses are shown in Fig. 3A and the data from 5 independent 
experiments are summarized in Fig. 3B.   MP1 and SR2-2GFP both contained intact 
GFP; most of the D17 cells infected with these viruses were positive for GFP expression, 
with an average of 79.6% ± 2.7% (standard error [SE]) and 97.7% ± 0.2% (SE), 
respectively.  In contrast, very few SR6-2wtLTR-infected D17 cells (0. 3% ± 0.1% [SE]) 
were positive for GFP expression since this virus did not contain GFP.  In all 
experiments, a high proportion of cells infected with SR5-FP-GF were positive in GFP 
expression, ranging from 65% to 78.1% with an average of 72.9% ± 2.4% (SE) (Fig. 3).  
Most of the MS2-FP-GF-no3R -infected cells were positive for GFP expression (88.4 to 
95.2%, with an average of 91.7% ± 1.2% [SE]).  These experiments demonstrated that, 
most of the time, GFP was reconstituted during reverse transcription of SR5-FP-GF and 
MS2-FP-GF-no3R RNA.  Therefore, the F region was used to mediate minus-strand 
DNA transfer during reverse transcription of these proviruses.    
In addition to the flow cytometry analyses, GFP expression of the cell colonies 
was also examined using fluorescent microscopy.  As expected, GFP expression was 
found in 0 of 369 (<0.1%) SR6-2wtLTR -infected colonies.  GFP expression was found 
in 667 of 828 (80.6%) MP1-infected colonies, 305 of 341 (89.4%) SR2-2GFP-infected 
colonies, 629 of 856 (73.5%) SR5-FP-GF-infected colonies, and 1002 of 1092 (91.8%) 
MS2-FP-GF-no3R-infected colonies.  The frequencies of GFP expression detected by 
microscopy were similar to those observed by flow cytometry analyses.   
Molecular characterization of minus-strand DNA transfer in SR5-FP-GF 
and MS2-FP-GF-no3R.  To directly analyze the molecular nature of minus-strand DNA 
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transfer, we isolated drug-resistant cell clones.  From these clones, a portion of the 
proviral genome containing the upstream LTR was amplified and sequenced to 
characterize the molecular nature of the transfer events (Fig. 4). 
Partial proviral structures from 13 SR5-FP-GF-infected cell clones were 
characterized; of the 13 clones, 4 were positive and 9 were negative for GFP expression 
as measured by fluorescence microscopy and flow cytometry.  All of the 4 proviruses that 
expressed GFP contained the expected structures and had U3-reconstituted GFP-R-U5 in 
the LTRs.  None of the 9 proviruses that were negative for GFP expression had the 
reconstituted GFP in their LTRs.  Six of the 9 proviruses had U3-GF-R-U5 in the LTRs, 
and the other 3 contained U3-FP-R-U5 in their LTRs.   
Viruses with U3-GF-R-U5 appeared to be the predicted structures for proviruses 
generated by weak-stop DNA mediated minus-strand transfers (Fig. 1B).  However, upon 
further analyses, these proviruses were probably generated by a different mechanism.  
These vectors were derived from the pLN series plasmids (33).  With the exception of 
pMS2-FP-GF-no3R, all of these vectors had an additional PBS directly downstream of 
the 3´ LTR (Fig. 5A), as well as sequence variation between the 5´ and 3´ R regions (Fig. 
5B).  In these vectors, there were two possible mechanisms to generate viral DNA with 
LTRs containing U3-GF-R-U5: weak-stop minus-strand DNA transfer, and readthrough 
RNA transcripts with DNA synthesis initiated from the downstream PBS.  Termination 
of retroviral RNA transcripts is known to be relatively inefficient; 15% of the total 
transcripts are read through the termination signal and contain sequences downstream of 
LTR (19).  In addition, it has been shown that these readthrough transcripts can be 
efficiently packaged into viral particles (20, 41, 42).  In SR5-FP-GF, these readthrough 
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transcripts would contain the entire downstream LTR and PBS (Fig. 5A).  If DNA 
synthesis initiated from the downstream PBS, RT would copy the entire downstream 
LTR and proceed to copy the rest of the viral RNA.  In this situation, reverse 
transcription would entirely bypass the step of minus-strand DNA transfer.  The resulting 
viral DNA would have U3-GF-R-U5 in the LTRs  (Fig. 5A), similar to the viral DNA 
generated from the weak-stop DNA transfer.  The difference between these two viral 
DNAs was the origin of R in the LTR.  With the weak-stop DNA transfer, a portion of R 
would be from the upstream R and another portion would be from the downstream R 
(Fig. 5A).  With readthrough RNA transcripts and downstream PBS initiation, however, 
the entire R sequence would be derived from the downstream LTR.  When we compared 
the R sequences of the 6 proviruses, all of them were entirely derived from the 
downstream R, indicating that these proviruses were generated by readthrough RNA 
transcripts and downstream PBS initiation rather than by weak-stop minus-strand DNA 
transfer.    
Three of the 9 proviruses had U3-FP-R-U5 in the LTRs; these were likely to be 
generated from RNA transcripts initiating from the promoter upstream of U3, termed 
read-in transcripts (Fig. 6).  We hypothesized that in the virus-producing cells, some 
transfected pSR5-FP-GF might integrate close to the promoters.  Read-in transcripts 
would therefore contain the upstream U3 sequences along with FP, R, and U5.  During 
reverse transcription, minus-strand DNA synthesis would copy U5, R, FP, and a portion 
of U3.  The complementarity between the newly synthesized U3 DNA and U3 near the 3´ 
end of RNA could be used to mediate minus-strand DNA transfer.  The resulting provirus 
would have two LTRs containing U3, FP, R, and U5.   
 54
The molecular nature of minus-strand DNA transfer was also examined in 18 
MS2-FP-GF-no3R-infected cell clones.  Of these clones, 9 were positive and 9 were 
negative for GFP expression by both fluorescence microscopy and flow cytometry 
analyses.  Similar to the SR5-FP-GF-infected clones, all of the 9 MS2-FP-GF-no3R 
proviruses that expressed GFP had precisely reconstituted GFP in the LTRs.  Of the 9 
MS2-FP-GF-no3R proviruses that did not express GFP, two had mutations in GFP:  One 
had a reconstituted GFP that contained a G-to-C substitution mutation in the G region 
that converted a glycine to an arginine and thereby inactivated GFP; the other contained a 
mutant GFP with a 120-bp deletion in the P region.  The structure of the LTR from the 
latter provirus contained U3, G, F, 52 bp of 5´ P, a 120-bp deletion within P, 205 bp of 3´ 
P, R, and U5.  Because the junction between F and P as well as the junction between P 
and R remained intact, the deletion was probably independent of minus-strand DNA 
transfer.  The other 7 MS2-FP-GF-no3R proviruses had a U3-FP-R-U5 structure in the 
LTR similar to those in SR5-FP-GF, which were presumably generated from read-in 
RNA transcripts.   
Because the 3’ R, U5, and PBS were deleted in pMS2-FP-GF-no3R, proviruses 
with U3-GF-R-U5 structure in the LTRs were not observed.  This impacted the frequency 
of the GFP-expressing cells.  Approximately 8% and 27% of the cells infected with MS2-
FP-GF-no3R and SR5-FP-GF did not express GFP, respectively (Fig. 3).  The 19% 
difference between the cells infected with MS2-FP-GF-no3R and SR5-FP-GF is close to 
the percentage of SR5-FP-GF proviruses containing the U3-GF-R-U5 structure in LTRs.  
Thus, the increase in the frequency of gene reconstitution in MS2-FP-GF-no3R was 
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directly correlated to the lack of readthrough transcription and initiation from the 
downstream PBS which generated proviruses with U3-GF-R-U5 LTRs.   
Efficient minus-strand DNA transfers mediated by nonviral sequences. 
Analyses of GFP expression in cell populations infected with SR5-FP-GF and MS2-FP-
GF-no3R indicated that GFP was reconstituted at approximately 72.9% and 91.7% 
efficiencies, respectively.  Molecular characterization of 13 GFP-expressing proviruses 
generated from SR5-FP-GF or MS2-FP-GF-no3R demonstrated that these proviruses 
contained precisely reconstituted GFP, indicating that the F region was used to mediate 
minus-strand DNA transfer in these viruses.  In one round of replication, MS2-FP-GF-
no3R generated titers similar to SR5-FP-GF and SR2-2GFP, which could use either the R 
or F region to mediate minus-strand DNA transfer.  Taken together, these data 
established that the F region could be used to mediate minus-strand DNA transfer in an 
efficient manner.  In addition, these data demonstrated that minus-strand DNA transfer 
could be used as an effective means to reconstitute genes during virus replication.  
  
DISCUSSION 
In this study, we intended to define the requirement of sequence context of the R 
region in mediating minus-strand DNA transfers.  The current model postulates that the 
role of the R regions is to provide complementarity between the newly synthesized 
minus-strand DNA and the 3´ R of the viral RNA to align the reverse transcription 
complex for accurate switching of the RNA template.  This view suggests that the two R 
regions allow the hybridization of the nascent DNA and the 3´ RNA.  In this model, it is 
likely that R is required to exceed a certain length to allow precise and efficient 
 56
DNA/RNA alignment, but it is unlikely that R must contain specific sequences for the 
hybridization of nascent DNA and viral RNA.  This prediction, however, was 
contradicted by an in vitro study suggesting that nonviral sequences could not mediate 
minus-strand DNA transfer (3). 
Using a series of MLV vectors with modified LTRs, we demonstrated that a 
nonviral sequence, a portion of GFP, can efficiently mediate minus-strand DNA transfer.  
This finding is in contrast with the in vitro study in which the nonviral sequence was 
unable to mediate minus-strand DNA transfer.  It is possible that this difference reflects 
the experimental systems employed in the two studies.  In the in vitro system, strand 
transfer depended solely on the interactions between RT, NC, and nucleic acids.  In our 
system, viruses containing the vector RNA were used to infect target cells; most of the 
DNA synthesis, including the strand transfer steps, was conducted within the reverse 
transcription complex in the cells.  Many factors present in the in vivo but not in the in 
vitro system, such as the configurations of the RNAs and reverse transcription 
complexes, were very likely to be important in minus-strand DNA transfer.  Therefore, 
the contrast of the two studies emphasizes the important roles of the elements missing in 
the in vitro assays.     
Readthrough RNA transcripts and downstream PBS initiation.  During the 
analyses of SR5-FP-GF-generated proviruses, we observed LTRs with U3-GF-R-U5 
structures.  Despite the resemblance of the predicted structures, these proviruses were 
unlikely to be generated by weak-stop minus-strand DNA transfer.  The two R regions in 
the vectors we used contained sequence variation scattered throughout the length of the 
two R regions.  During minus-strand DNA synthesis, the first difference in the two R 
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sequences that RT would encounter was at nt 6 at the 3´ end of R (T for upstream R and 
G for downstream R).  In order for a provirus to contain R regions with all of the markers 
from the downstream R, DNA synthesis would have to stop before nt 6 of the upstream R 
and use less than 6-nt complementarity between nascent DNA and 3´ RNA to mediate 
minus-strand DNA transfer.  However, we have observed in other studies that a 6-nt 
homology is not sufficient to mediate accurate and efficient minus-strand DNA transfer 
(8).  Therefore, these proviruses were likely to be generated by other mechanisms.   
We propose that these proviruses were generated from readthrough RNA 
transcription with DNA synthesis initiating from the downstream PBS.  We have 
previously observed efficient initiation of DNA synthesis from the downstream PBS (V. 
K. Pathak, P. D. Yin, R. J. Teufel II, and W.-S. Hu, unpublished data).  Approximately 
27% of the SR5-FP-GF-infected cells did not express GFP (Fig. 3).  Of the 9 proviruses 
analyzed, 6 had the U3-GF-R-U5 structure.  Therefore, approximately 18% of the 
proviruses had the U3-GF-R-U5 structure, close to the observed 15% efficiency of 
readthrough RNA transcription (19).  This result also suggested that DNA synthesis of 
these readthrough RNA transcripts mostly initiated from the downstream PBS and 
bypassed the minus-strand DNA transfer event.  This was possible because the 
downstream PBS in these vectors contained a large portion of the sequences proposed to 
form a secondary structure that was important for efficient initiation of DNA synthesis.  
In addition, the GF fragment is 350 bp in length, whereas FP is 462 bp.  If DNA synthesis 
initiated from both upstream and downstream PBS simultaneously, there would be a race 
for the 3´ template usage.  By the time DNA synthesis that was initiated from the 
upstream PBS reached the end of FP, DNA synthesis that was initiated from the 
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downstream PBS would have copied through GF and a portion of U3.  Consequently, the 
RNA templates at the 3´ end of the viral sequences would be degraded, including the F 
region of the RNA that could be used for minus-strand DNA transfer.  Therefore, it was 
likely that the minus-strand DNA that was initiated from the upstream PBS would lose 
the “race” during reverse transcription, which may account for the proportion of 
proviruses that contained sequences derived from the downstream R.   
Alternatively, it is possible that in readthrough RNA transcripts, minus-strand 
DNA synthesis initiated from the upstream PBS, copied a portion of U5, and used the U5 
sequences to transfer to near the 3´ end of the viral RNA.  RT could then copy the 3´ R, 
GF, and U3 sequences.  In order for this mechanism to account for most of the proviruses 
containing U3-GF-R-U5 in the LTR, minus-strand DNA transfer had to occur at a high 
frequency during the copying of the 72-nt U5 region.  Because minus-strand DNA 
transfer mediated by weak-stop DNA is known to occur at a low frequency while copying 
R, which is 68 nt in length, this mechanism is unlikely to be responsible for generating all 
of these proviruses.   
Read-in RNA transcripts and minus-strand DNA transfer using the 
homology region including a portion of U3.  In this study, we also observed proviruses 
containing U3-FP-R-U5 LTR structures.  We hypothesized that these proviruses were 
generated from RNA transcripts that were initiated from upstream promoters.  In another 
study from our laboratory, modified MLV vectors lacking the downstream U3 were used 
to examine minus-strand DNA transfer (8).  Some of the proviruses resulting from that 
study contained portions of U3 sequences, indicating that these proviruses were also the 
products of read-in RNA transcripts.  In addition, RNA species containing the upstream 
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U3 were identified in cellular RNA samples by RNase protection assays, further 
confirming our hypothesis.     
This observation raised the question of whether U3 sequences are occasionally 
used in minus-strand DNA transfer during the replication of wild-type viruses.  If an 
active promoter is located upstream of a provirus, RNA transcripts containing the 
upstream U3 could be easily generated.  However, most of these transcripts would 
terminate at the 5´ R; only 15% of the transcripts would read through the 5´ R and 
terminate at the 3´ R.  Similar to the events observed in our experiments, RT could copy a 
portion of the upstream U3 and use the U3 sequences to align the nascent DNA and 3´ 
RNA for minus-strand DNA transfer.  Because these events depend on both the location 
of the proviral integration and the RNA transcript extending through 5´ R, if U3 were 
used to mediate minus-strand DNA transfer in wild-type viruses, it would be likely to 
occur at a low frequency.      
Application of minus-strand DNA transfer-mediated gene reconstitution to 
gene therapy and inducible gene expression systems.  Previously, direct repeat 
deletion has been utilized to reconstitute various genes with a high efficiency; these genes 
included the drug-resistance gene neo and a suicide gene encoding the herpes simplex 
virus thymidine kinase that has been used for cancer therapy (10-12, 25).  This strategy 
uses high frequency template switching events that occur during reverse transcription to 
reconstitute genes and delete sequences from the portions of the viral genome that are 
internal to the LTRs.  In this report, we describe gene reconstitution using a different 
strategy utilizing the obligatory minus-strand DNA transfer step in the reverse 
transcription process.  GFP was reconstituted at approximately 92% efficiency in the 
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vector pMS2-FP-GF-no3R.  This high-frequency reconstitution could be exploited for 
gene delivery in gene therapy applications or as an inducible gene expression system.  In 
the plasmid vector, a gene of interest or a cassette containing a gene expression unit could 
be divided into two portions with a small stretch of overlapping sequences in which 
neither portion could express the gene of interest.  During reverse transcription and virus 
replication, this gene of interest could be reconstituted and expressed in the infected cells.  
Such an approach could be very useful for the delivery of potentially toxic genes in gene 
therapy applications in which the toxicity of the gene hampers the production of the viral 
vector-containing virions.  This approach could also be very useful as an inducible gene 
expression system in which viral replication activates gene expression.  Because the 
reporter gene is inactive prior to virus replication, there would be little background 
expression in the system.  For example, this strategy could be used to detect the presence 
of replication-competent retroviruses (RCR).  Test samples could be applied to target 
cells transfected with pMS2-FP-GF-no3R; if RCR is present in the sample, then MS2-FP-
GF-no3R would be mobilized and the infected cells would express GFP.  This could be 
performed in a one-step assay to directly detect RCR rather than a lengthy co-culture or 
infection assay.    
In summary, we have established that homology, rather than sequence context, is 
important in the mediation of efficient minus-strand DNA synthesis.  During this study, 
we also demonstrated that genes can be reconstituted during minus-strand DNA transfer 
efficiently with a short stretch of homology, a strategy that could also be exploited for the 
design of gene therapy vectors.    
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FIGURE LEGENDS 
FIG. 1.  MLV-based vectors and strategy used to study the requirement of 
sequence context in mediating minus-strand DNA transfer.  (A) Structures of the MLV-
based vectors.  SV, SV40 promoter; hygro, hygromycin phosphotransferase B gene; GFP, 
green fluorescent protein gene; GF, the 5´ 350-bp fragment of GFP; FP, the 3´ 462-bp 
fragment of GFP; SV-ter, SV40 termination signal; Ψ+, the extended MLV packaging 
signal; IRES, internal ribosomal entry site; neo, neomycin phosphotransferase gene.  (B) 
Strategy used to test the ability of nonviral sequences to mediate minus-strand DNA 
transfer.  The structure of pSR5-FP-GF is illustrated at the top.  Either minus-strand DNA 
transfer would be mediated by strong-stop DNA and the GFP would therefore be 
reconstituted, or minus-strand DNA transfer would be mediated by weak-stop DNA and 
the GFP would not be reconstituted.   
FIG. 2.  Experimental protocol.  Virus was harvested from transfected PG13 
helper cells and used to infect D17 target cells.  Viral titers were determined by the 
number of drug-resistant colonies and standardized to the RT activities.  GFP expression 
in infected target cells was analyzed by flow cytometry and fluorescence microscopy.  
Minus-strand DNA transfer junctions were analyzed in infected cell clones.   
FIG. 3.  Flow cytometry analyses of infected cells.  (A) A representative set of 
flow cytometry analyses using cells infected with MP1, SR6-2wtLTR, SR2-2GFP, SR5-
FP-GF, and MS2-FP-GF-no3R.  In each plot, the Y axis is the number of events scored, 
which is interpreted as the number of cells, and the X axis is the intensity of the 
fluorescence.  (B) The proportion of fluorescent cells infected with various vectors from 
5 independent sets of infections.  Error bars represent the standard error of the average.   
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FIG. 4.  Strategy for PCR amplification of proviral LTRs and DNA sequencing.  
All abbreviations are the same as in Fig. 1.  Zigzag lines, host DNA sequences; large 
arrows, PCR primers; small horizontal arrows, sequencing primers.   
FIG. 5.  Two models for the generation of proviruses with U3-GF-R-U5 in the 
LTRs.  (A) Illustration of the two models.  All abbreviations are the same as in Fig. 1.  
Sequences derived from upstream R are shown in gray, whereas sequences from 
downstream R are shown in white.  (B) Sequence comparisons of the upstream and 
downstream R regions.   
FIG. 6.  Model for generating proviruses with U3-FP-R-U5 by using read-in RNA 
transcripts.  All abbreviations are the same as in Figs. 1 and 4; pro, upstream promoter.  
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TABLE 1. Primers used for vector construction, PCR amplification, and DNA 
sequencing 
Primer name  Sequence 
GFPp1-AscI 5´-TCTCCGAATGGCGCGCCGCCACCATGAGCAAGGGC-3´  
PFG2p-csA 5´-CCTATCTCGAGGCGCGCCTCACTTGTACAGCTCGTCCATG-3´ 
GFPp3-EheI 5´-ATCCCGAATCGGCGCCGCCACCATGAGCAAGGGC-3´  
PFG4p-ehEI 5´-GTCATGTCAAGGCGCCTCACTTGTACAGCTCGTCCATG-3´ 
FPAscp1 5´-ATATAGGCCTGGCGCGCCATGCCCGAGGGCTATG-3´   
FG-ehE-4p 5´-CGGTAGCAATGGCGCCAACTTGACTTCAGCGCGGGTC-3´   
MLVU3  5´-ATGTTTCCAGGGTGCCCCAAGGACC-3´ 
IspVLM5´  5´-TCAAACATAGACACTAGACAATCGG-3´ 
GF101 5´-CAGCGGAGAGGGTGAAGGTG-3´ 
5UVLM  5´-TCGTGGGTAGTCAATCACTCAGAGG-3´ 
R/3UM-629  5´-CGACGCAGTCTATCGGAAGACT-3´ 
PFG-695 5´-CATGCCATGTGTGATCCCAGC-3´  
PFG-464 5´-TTGTGCGCCATGATGTACAC-3´ 
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TABLE 2.  Viral titers generated by PG13 cells transfected with vector plasmidsa 
Viral Titers (× 104 CFU/ml) 
Exp. 
MP1 SR6-2wtLTR SR2-2GFP SR5-FP-GF MS2-FP-GF-no3R 
A 72 12 NDb 2.6 1.3 
B 44 19 4.9 1.0 4.7 
C 16 8.3 4.1c 13 11 
D 43 17 5.9 4.0 3.2 
E 130 130 14 24 21 
 
   a Within each set of experiments, the viral titers  were standardized to the RT activities.  
In general, within each set of experiments, RT activities were within 20% of the 
differences among the samples.     
   bNot determined. 
   cThis titer measurement was not standardized to RT activity.  
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ABSTRACT 
  
We synthesized several murine leukemia virus (MLV) and spleen necrosis virus 
(SNV) pol mutants in the reverse transcriptase (RT), RNase H and integrase (IN) 
domains in order to investigate whether Pol polyproteins from MLV could co-package 
and cooperate with Pol polyproteins from SNV to complete reverse transcription.  A 
previously published chimeric SNV/MLV virus gag-pol expression vector system was 
utilized to investigate the co-assembly properties of these two viruses (Certo et. al, 
J.Virol., 72:73, 1998). 
Western blotting, RT assay, and real-time PCR of reverse transcription products 
in infected cells examined the phenotypes of several SNV and MLV pol mutants. In both 
SNV and MLV IN, mutations of the Zn2+ finger caused a gag-processing defect, while IN 
catalytic core mutants were processed with efficiency similar to that of wild type IN.  
When early and intermediate reverse transcription products were compared to the total 
RT activity, the  Zn2+  finger and catalytic core mutants did not display a defect in 
initiation of reverse transcription or minus-strand transfer.  A mutation in SNV RNase H 
exhibited no processing defects and was found to be deficient in minus-strand transfer. 
We also attempted to rescue the IN and RNase H mutants by complementation 
with an MLV pol vector that contained a mutation catalytic site of RT (D150E).  Rescue 
of the SNV IN, SNV RNase H and MLV IN mutations was observed at a low rate, 
indicating that it was possible for the pol gene products from two different retroviruses to 
assemble into one virion.  Because the MLV Pol could be weakly complemented with 
either SNV or MLV RT at roughly equal efficiencies, there was apparently no preference 
for the homologous RT.  Furthermore, whether the Zn2+ finger or catalytic core of IN was 
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mutated seemed to have little effect on the efficiency of complementation.  In summary, 
despite being genetically distinct viruses with little sequence homology (42%) in their pol 
genes, SNV and MLV Pol proteins could co-assemble into virions and cooperate to 
complete reverse transcription, which indicates that crucial protein-protein contacts in the 
reverse transcription complex are conserved between these two viruses. 
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 INTRODUCTION 
 All retroviruses contain at least four functional genes- gag, pro, pol, and env.  The 
gag gene encodes viral structural proteins, while the pol encodes the viral enzymatic 
machinery for replication.  The gag of murine leukemia virus (MLV) is comprised of 
matrix (MA), p10, capsid (CA), and nucleocapsid (NC) proteins.  The pol of retroviruses  
encodes the reverse transcriptase (RT), ribonuclease H (RNase H), and integrase (IN) 
proteins.  The pro encodes the viral protease, which cleaves the polyproteins to their 
smaller proteins.  The Pol polyproteins are always synthesized from a Gag-Pol precursor 
protein, and Gag is synthesized about 10 to 20 times more often than Gag-Pol (11, 13, 
21).  The incorporation of Pol into viruses is therefore dependent on Gag expression.  
Following translation of these proteins in gammaretroviruses, they traffic to the plasma 
cell membrane, where budding occurs.  The Gag and Gag-Pol polyproteins bud from the 
cell membrane, and during this assembly process, the viral protease is activated and the 
polyproteins are cleaved to their smaller products, which allow maturation of the virus 
cores.  This maturation process can be seen by electron microscopy; a mature virus has an 
electron-dense staining core in the center of the virus, while an immature particle lacks 
the electron-dense core (8, 15, 20, 22, 25, 28, 30).  
 It has been shown that Gag proteins from two different viruses cannot co-
assemble into the same virus particle.  For MLV and Spleen Necrosis Virus (SNV), it has 
been shown that the two Gags cannot co-assemble and that their ability to package RNA 
is non-reciprocal.  MLV Gag can only package MLV genomic RNA, whereas SNV Gag 
can package SNV and MLV genomic RNA (5).  Use of an SNVgagMLVpol expression 
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vector in a cell line that expressed both MLV vector RNA and SNV vector RNA 
demonstrated that the SNV Gag proteins were capable of recognizing both SNV and 
MLV viral RNA with equal efficiency.   
 It is possible to use trans-complementation systems to study virus replication (12, 
17, 27, 29).  Use of such systems allows determination of the roles of different proteins 
during reverse transcription in vivo.  It was previously shown that RT and RNase H from 
two different Gag-Pol precursors could complement extremely well in vivo.  One 
construct carries a mutation in the RH domain of pol, the other in the RT domain.  When 
each is transfected into cells expressing an MLV vector RNA, viruses produced from the 
cell line carry both mutants.  Furthermore, these Pol-mixed virions are able to replicate. 
Other labs have shown that RT and IN can complement each other in trans quite 
efficiently (17, 27, 29) either by use of two different Gag-Pol expression constructs in a 
cell line or by use of a vpr-IN fusion protein for HIV or Gag∆NC-IN fusion protein for 
MLV.   
It was of interest to determine whether the RT and IN proteins of SNV and MLV 
could functionally complement each other because pleiotropic effects on virus life cycle 
from IN mutations have been widely described in the literature (for review, see reference 
(6).  For HIV-1, mutating the conserved HHCC motif (which putatively forms a Zn2+-
finger) of the IN protein abrogated viral DNA synthesis and integration activity in 
infected cells.  However, mutating any of the conserved central catalytic core residues by 
substitution caused only a loss of integration- not reverse transcription (29).  Somewhat 
differing results were found for MLV IN; mutation of either the catalytic core or the 
HHCC motif did not cause a loss of viral DNA synthesis (17).  In contrast, the C-terminal 
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domain of MLV IN appeared to be required for viral DNA synthesis.  Mutations in the 
HHCC motif of IN have been shown to cause defects in virus protein processing (23), 
and deletion of the IN-coding domain from HIV-1 can cause a loss of processing 
altogether (3).  Because of these pleiotropic effects of IN mutations, the IN mutations 
generated to establish the RT/IN complementation system were chosen carefully.  
SNV and MLV are two very distantly related members of the gammaretrovirus 
family.  Although they contain little homology in their pol genes (53%), the SNV RT and 
IN are able to mediate reverse transcription of MLV RNA as well as the MLV Pol 
proteins.  Therefore, it should be possible to establish an RT/IN complementation system 
using SNV and MLV Pol proteins and MLV vector RNA.  Complementation of the RT 
and IN of SNV with the RT or IN of MLV would demonstrate that although there is little 
sequence homology between these two viruses, crucial protein contacts in the reverse 
transcription and pre-integration complex are conserved  
We seek to determine if the Pol proteins from MLV and SNV could also co-
assemble and form infectious virions. In order to do this, it will be necessary to establish 
a complementation system that requires assembly of different species of Pol into the 
same virus for production of infectious virions.  We wished to see if a chimeric RT/IN 
complementation system from SNV and MLV could be used to demonstrate that SNV 
and MLV Pol proteins could co-assemble into the same virus and if the RT from SNV or 
MLV could complement the MLV or SNV IN during reverse transcription and 
integration.    
Two Gag-Pol expression constructs were used to study complementation between 
RT and IN in these experiments.  The first is RD136, an SNV gag-pol construct, and the 
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second is SNVgagMLVpol. A panel of Pol mutants was constructed in both of these 
vectors in order to determine if Pol proteins from SNV could co-assemble with Pol 
proteins of MLV. Furthermore, the replication properties of these mutants were 
determined, and they were used in a trans-complementation system to study the 
efficiency with which Pol proteins from SNV could functionally replace Pol proteins 
from MLV. 
 
MATERIALS AND METHODS 
 
Vector Construction.  Cloning was carried out using standard methods (24).  All SNV 
gag-pol expression vectors were derived from pRD136, and all SNV-gag MLV-pol 
chimeric vectors were derived from pSNVgag.  All primers used for cloning are shown in 
Table 1, and the vectors are shown in Fig. 1A. Vector pSR7-D150E was subcloned from 
an MLV D150E RT mutant by excising the fragment between two BstEII sites and 
inserting the fragment from the MLV-D150E vector that had been created by a similar 
BstEII digestion and treated with Calf Intestinal Phosphatase (Roche).  The SR7-D150E 
clone contained a new Bst1107I site and mutated the Aspartate (D) residue at position 
150 to a Glutamate (E).  The LC2 vector contained a 4-amino acid insertion between the 
two Cysteine residues of the HHCC motif in IN.  This insertion was made by annealing 
two oligonucleotides to create the linker 5’-AGC TGG TAT ACC-3’, which was inserted 
between the GCA and AGC residues of the HHCC motif.  pSNVgag was partially 
digested with HindIII, and the linker was inserted at  nt 5165, which generated a unique 
Bst1107I site.  The SR13 vector encoded a substitution mutation in the D125 residue of 
IN to an alanine (A), which was obtained by PCR mutagenesis.  Briefly, the primer 
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SNVgag-4421 and D125AMLVIn for were used to PCR amplify a fragment from nt 4421 
to 5253 of pSNVgag.  Primers D125AMLV In rev and SNVgag6060C were used to PCR 
amplify a fragment from nt 5253 to 6060;these two fragments were joined together in a 
subsequent PCR reaction with primers SNVgag4421 and SNVgag6060C.  The PCR 
product was digested with Bpu1102I and PmlI.  The product also contained an additional 
BsmI site that did not change the coding region and was used to identify mutants 
containing the new mutation. The fragment containing the substitution was cloned into 
pSNVgag, which had been digested with Bpu1102I and PmlI. 
 The RD136YVNN vector was constructed via the Stratagene Quickchange 
mutagenesis kit.  This vector incorporated two substitution mutations in the YVDD motif 
of RT- the two aspartic residues were changed to asparagine residues.  Briefly, the 
mutagenic primer contained the substitution mutations and another primer knocked out a 
HindIII site at nt 5684 in pRD136.  The PCR product contained an HpaI site at 3495 for 
screening.  The fragment was digested with Asp718 and Bst1107I and ligated into 
pRD136, which had been digested with Asp718 and Bst1107I and treated with CIP.  
  The SR8 vector was constructed by partial digestion of RD136 with SphI, and 
insertion of a linker between the two C residues of the HHCC motif that inserted 4 amino 
acids (tryptophan, methionine, histidine, and alanine).  The linker was formed by 
annealing IN-minus-5’  to IN-minus-3’.  Insertion of the linker added a BamHI site to the 
vector.   
The SR12 integrase mutant incorporated a substitution at D109 to A.  This 
substitution was generated by PCR mutagenesis that simultaneously introduced a BsmI 
site into the vector.  The primer Nerd136-4372 and primer D109ASNVInfor were used to 
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amplify a DNA fragment from bp 4372 to 5209 of pRD136.   Similarly, primers 
Nerd136-5475C and D109ASNVInrev were used to amplify another DNA fragment from 
nt 5209 to 5475 of pRD136.  The two PCR products were joined together in a subsequent 
PCR reaction with Nerd136-4372 and Nerd136-5474C.  This fragment was digested with 
SgrAI and AgeI. The digested product was cloned into RD136 that had been digested 
with SgrAI and AgeI.   DNA sequence analysis and restriction enzyme mapping 
confirmed all mutations and ensured that no other mutations had been introduced during 
cloning procedures. 
Tissue Culture. The A3-4 clone of the GFFP cell line (31) was used for all transfections.  
These cells were maintained in Dulbecco’s Modified Eagle’s Media (DMEM) 
supplemented with 6% calf serum and 50 µg/mL streptomycin and 50 U/mL of penicillin.  
G418 selection was done at a concentration of 600 µg/mL and hygromycin selection was 
done at 120 µg/mL.  Ouabain selection was performed at 73 µg/mL.  Briefly, the GFFP 
cell line contains a copy of p-SV-A-MLV, which expresses amphotropic MLV envelope, 
and an MLV vector that carries the gene for neomycin resistance and the gene for green 
fluorescent protein (GFP) that has been divided into two fragments which contain 
overlapping homology to measure direct repeat deletion.  The SNVgagD150E cell line 
was derived from the A3-4 GFFP cell line by transfection of SR7-D150E into the GFFP 
cells by DMSO-Polybrene transfection (2).  SR7-D150E was co-transfected at a 10:1 
ratio into the cell line with pSVα3.6, which encodes the gene for the Na+/K+ pump and 
confers resistance to ouabain selection (ref).  Cells were selected with ouabain 48 hours 
following transfection and pools of resistant cells were obtained.  These cells were known 
as the SNVgagD150E cell line.   
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 All vectors were co-transfected either into the GFFP cell line or the SNVgag-
D150E cell line by DMSO-Polybrene method with the SV-hygro plasmid, which carries 
the gene for hygromycin phosphotransferase B (9), at a 10:1 (gag-pol vector: pSVhygro) 
ratio.  Cells were selected for hygromycin resistance 24 hours following transfection, and 
pools of these cells were obtained for mutant and complementation analysis. 
 A portion of the A3-4 GFFP cells that were transfected with RD136-YVNN were 
maintained as the YVNN cell line, in order to test for SNV homologous 
complementation.  These cells were co-transfected with each pol mutant vector and 
pSVα3.6 and selected for ouabain resistance.  All cells containing gag-pol expression 
vector constructs were maintained in AZT to prevent reinfection of producer cells. 
Virus harvest and analysis. Virus-producing cells were plated to five 100-mm tissue 
culture plates, at a density of 5 X 106 cells per plate.  Each plate of cells was fluid 
changed 24 hours following the plating with 8 mls of fresh media, and D17 cells were 
plated to 60 mm dishes, at a density of 1 X 105 cells per dish.  Media containing the 
viruses were harvested 24 hours following this fluid change from the virus producing 
cells.  The virus-containing supernatants were clarified by low-speed centrifugation 
(4000 RPM for 10 minutes) or by filtering through a 0.45µm filter (Corning).  An aliquot 
of the virus was serially diluted in the presence of 50 µg/mL polybrene and used to infect 
the D17 cells for four hours.  Following infection, virus-containing media was aspirated 
from the D17 cells and replaced with fresh media.  Twenty-four hours following infection 
the infected target cells were subjected to G418 selection to determine virus titers. 
 The remaining virus was concentrated in a Discovery 100S Preparative 
Ultracentrifuge (Sorvall) at 25,000 RPM at 4 degrees Celsius for 90 minutes, using a 
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Sorvall Surespin 630 rotor.  The pelleted virus was resuspended in media and used for 
Western blotting and RT assay. 
Real-Time PCR.  D17 cells were plated at a density of 5 X 106 cells per 100-mm dish 
and infected with 2 mL of virus in the presence of 50 µg/mL polybrene.  One hour 
following application of virus, the cells were fluid-changed with fresh media.  Six hours 
following infection, cells were lysed and total DNA was harvested using the Qiagen 
Blood Mini Kit, according to manufacturer’s specifications.  DNA was used in a Prism 
ABI 7700 real-time PCR to detect products of reverse transcription. 
Table of primer sequences here. Primer-probe sets homologous to the R-U5 
region of the virus vector DNA were used to detect initiation of reverse transcription, and 
primers homologous to the 3’ of neo were used to detect minus-strand transfer and later 
products of reverse transcription.  All PCR reactions were carried out using the TaqMan 
PCR kits according to the manufacturer’s instructions.  PCR conditions were as follows:  
denaturation at 95 degrees Celsius for 10 minutes, followed by 40 cycles of 95 degrees 
for 15 seconds, and annealing and extension at 60 degrees for 60 seconds.  Standard 
curves were performed with pYV11, which contains one copy of the MLV LTR and the 
neomycin resistance gene.  All real-time PCR analysis was done with the ABI 7700 
software package. 
Reverse Transcriptase Assay.  Exogenous RT activities were determined by 
incubating 10 µl of virus with 50 µg/ml οf 20-mer oligo T (Integrated DNA 
Technologies), 100 µg/ml of poly(A) (Pharmacia), 60 mM NaCl, 50 mM Tris (pH 8.0), 1 
U/µl RNase inhibitor, 10 mM dithiothreitol, 0.6 mM MnCl2, 80 µM dTTP, 0.5% IGE Pal 
(Sigma), and 10 µCi of [3H]dTTP (72 Ci/mmol, ICN).  The samples were incubated at 
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37oC for 60 min. The reaction mixtures were precipitated with ice-cold 10% 
trichloroacetic acid (Sigma) and filtered through 0.45-µm-pore-diameter Metricel 
membranes (Gelman Sciences, Inc.); the amount of [3H] incorporated was determined 
using a Tricarb 1600 TR Liquid Scintillation Analyzer (Packard). 
Western Blotting.  Western Blotting was used to determine the amount of virus released 
by detection with antibodies to reticuloendotheliosis virus (REV) CA protein (a kind gift 
from Nancy Rice).  REV is a very close relative to SNV.  Briefly, a portion of the 
harvested virus was diluted 1:2 with Laemlli’s sample buffer (Biorad), heated to 99 
degrees Celsius for 5 minutes, and electrophoresed on a 1.5-mm thick 12% Tris-Glycine 
gel (Invitrogen).  Electrophoresis was performed for 90 minutes at 125 mV.  Following 
electrophoresis, the gel was transferred to PVDF blotting membrane using the Owl semi-
dry electroblotter for 2 hours at 125 mA.  Following transfer, the PVDF membrane was 
blocked in 5% milk in Tris-buffered Saline (TBS) for 12 hours, probed with 1:10,000 
rabbit α−REV CA antibody for 4 hours, washed 3 times with TBS-0.1% Tween-20, and 
incubated with 1:10,000 goat α-rabbit horse radish peroxidase for 60 minutes. The 
membrane was washed 3 times with TBS-0.1% Tween-20 for 5 minutes per wash and 
incubated with ECL-Plus Western Labeling Kit from Amersham Biosciences for 3 
minutes.  The blot was exposed to Kodak X-omat film.  The amounts of unprocessed Gag 
protein and processed Capsid protein were compared. 
Electron Microscopy.  To determine the morphology of the integrase mutants that had 
processing defects, electron microscopy (EM) was done on virus-producing cells and the 
relative number of immature vs. mature virus particles for each sample was determined.  
For each sample, at least 100 viruses were examined.  Briefly, 1 X 107 transfected cells 
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were collected, pelleted by low-speed centrifugation (1200 RPM for 2 minutes) and fixed 
by applying a solution of 2% glutaraldehyde in PBS to the top of each pellet.  Samples 
were paraffin embedded and sliced into thin sections for EM analysis. The EM was 
performed by the Science Applications International Corporation core facility at NCI-
Frederick. 
 
RESULTS 
 
Protocol for Characterization of Mutants.  A panel of vectors was constructed to study 
RT, RNase H, and IN complementation in both SNVgag-pol and chimeric SNVgag-
MLVpol expression vectors (Fig. 1A).  Briefly, RD136 is an SNV gag-pol expression 
construct.  YVNN is an RT mutant of RD136 in which the YVDD motif has been 
mutated to YVNN.  SR8 is an SNV  (IN) mutant that contains an insertion of four amino 
acids (W, M, H, and A) between the two C residues of the HHCC motif in SNV IN.  
SR12 is an SNV IN catalytic core mutant that contains a substitution of residue D109 to 
A.  The D109 residue constitutes the first catalytic core residue of the highly conserved 
D, D, 35E motif of SNV IN .  WZH73 is an SNV RNase H mutant that contains a 
substitution of residue D524 to N. 
 MP5 is a chimeric SNVgagMLVpol expression vector (5).  SR7-D150E is an RT 
mutant that contains a substitution of residue D150 to E.  This substitution has been 
shown to render the virus non-infectious (10).  LC2 is an MLV IN mutant that contains 
an insertion of 4 amino acids (A, G, I, P) between the coordinating C residues in the 
HHCC motif.  This mutation has been shown to have a processing defect with α-CA 
antibody by western blotting analysis, as well as reduced RT activity in vitro (23).  SR13 
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is an MLV IN catalytic core mutant which contains a substitution in the conserved D, D, 
35E motif of MLV IN catalytic core residue D125 to A.  Substitution mutations of the 
catalytic core of IN have been shown to eliminate virus integration activity, while having 
no effect on processing or RT activity (1, 4, 7, 16-19). 
 The approach utilized to analyze the replication properties of the vectors is 
outlined in Fig. 1B.  First, the ability of the mutants to support one cycle of replication 
was examined.  The phenotype of the D150E mutation was previously described (10).  
The mutants were separately co-transfected into the A3-4 GFFP cell line (26) with pSV-
hyrgro.  Pools of cells containing the stably expressed gag-pol expression vectors were 
obtained, and some of the cells were analyzed by EM to determine virion morphology. 
Virus was harvested from each pool, and infection of D17 cells, RT assay, western 
blotting, and real-time PCR were performed to examine the mutants’ infectivity, ability to 
produce virus, and the ability to carry out reverse transcription.    A portion of the 
infected D17 cells were selected with G418 to detect productive infection, and a second 
portion of the infected D17 cells was lysed 6 hours post-infection to obtain total cellular 
DNA for quantitative real-time PCR.  Real time PCR was used to measure the ability of 
these mutants to carry out reverse transcription.   
Protocol for Complementation Assays of RT and IN mutants.  Following the 
phenotype determination of these mutants, the SNVgag-D150E cell line was used for 
complementation experiments (Fig. 1C). The SNV-gag-D150E cell line expresses a 
defective MLV RT and wild type MLV IN from the SR7-D150E mutant.  For 
complementation analysis, the IN and RNase H pol mutants were each co-transfected 
with pSVhygro into the SNVgag-D150E cell line separately (Fig 1C).  Pools of these 
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cells were obtained for each mutant.  Viruses harvested from these cell pools should 
contain a mix of the Gag-Pol containing the D150E mutation, and the gag-pol containing 
the RNase H mutation or the IN mutations.  These mixed viruses were used to infect D17 
cells to determine titer by G418 selection and virion RT activity. 
Titers of Pol Mutants. The titers of the viruses carrying the SNV and MLV Pol 
mutations are shown in Table 2.  Titers were determined by three to six independent 
experiments.  The titer for RD136, the SNV wild type gag-pol expression construct, was 
2.3 X 103 cfu/mL.  The titer of the SNV RNase H mutant, WZH73, was 2.3, or 1000-fold 
less than wild type RD136.  The SR8 SNV HHCC IN mutant and the SR12 SNV IN 
catalytic core mutant had a titer of <1 cfu/mL.  Similarly, while the wild type SNVgag-
MLVpol vector MP5 had a titer of 6.6 X 103, both the LC2 IN HHCC insertion mutant 
and the SR13 IN catalytic core mutant had titers of <1 cfu/mL.  The titer assays 
confirmed that these Pol mutations were lethal to virus replication. 
RT Activity of Pol Mutants.  Virus preparations derived from Pol mutants were 
subjected to RT Assays.  The results of the RT assays, determined in three to six 
independent experiments, are presented in Table 2.  The values of the RT assay for each 
mutant are reported relative to SNV wild-type RD136 (set to 100%) RT activity.  The RT 
activity of the YVNN RT mutant was 4.9% of wild type.  The WZH73 SNV RNase H 
mutant RT activity was 272% of wild type.  The RT activity of SR8 SNV IN HHCC 
mutant was 10% of wild type.  The RT activity of SR12, the SNV IN catalytic core 
mutant, was 425% of wild-type activity.  For the two mutants that showed RT activity 
significantly higher than wild type, the western blot profiles demonstrated that more virus 
was being produced for each set because of differences among transfection efficiencies 
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(see appendix).  The RT activities for the MLV Pol mutants are also shown in Table 2. 
The RT activity of the wild-type MP5 has been normalized to 100%.  The LC2 IN HHCC 
insertion mutant virus had an RT activity of 24%, and the SR13 IN catalytic core 
substitution mutant had an RT activity of 35% of wild type.    
For all the RT activities, only the YVNN and SR8 SNV IN HHCC insertion 
mutant had an RT activity that was significantly lower than wild type (4.9%, and 10% of 
wild type, respectively).  The diminished RT activity of the YVNN mutant was not 
surprising, as this mutation disrupted the catalytic core of the RT protein.  This result 
suggested that the IN mutation in SR8 led to a reduction in either the production of RT or 
the enzymatic activity of RT. 
Mutations in the HHCC domain of IN result in processing defects.  The western 
blotting analysis for the MLV mutants is shown in Fig. 3A, and the analysis for SNV 
mutants is shown in Fig. 2B.  The analysis of MP5 virus showed no detectable processing 
defects, and a band corresponding to p30 CA is evident (Fig 3A, lane 1).  In contrast, 
analysis of the LC2 IN insertion mutant indicated that the p30 CA band was diminished, 
and a band corresponding to unprocessed Gag at p55 was evident (Fig 3A, lane 2).   This 
suggested that the IN mutation present in LC2 resulted in a processing defect.  Fig 3A, 
lane 3 shows the analysis of SR13, the IN catalytic core mutant.  This mutant had a 
processing profile similar to wild-type.  
 The analysis of RD136 wild type virus showed no detectable processing defects, 
and a band corresponding to p30 CA is evident (Fig 3B, lane 1).  In contrast, analysis of 
the SR8 HHCC IN insertion mutant indicated that the p30 CA band was diminished, and 
a band corresponding to unprocessed Gag at p55 was evident (Fig 3B, lane 2).  This 
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suggested that the IN mutation present in SR8 resulted in a processing defect.  Fig 3B, 
lane 3 shows the analysis of SR12, the IN catalytic core mutant.  This mutant had a 
processing profile similar to wild type.  Therefore, the HHCC motif mutants (LC2 and 
SR8) and the catalytic core mutants (SR13 and SR12) for SNV pol and MLV pol have 
the same processing phenotype.  The western blot profile of WZH73 was also 
determined; it has processing activity equivalent to wild type (data not shown). 
Virion Morphology.    In order to see if the processing defects observed for SR8 and 
LC2 resulted in altered virion morphology, transfected cells producing the IN mutant 
viruses were examined by EM (Table 3).  A total of 100 particles each for the MP5 wild 
type, SR8 SNV HHCC mutant, and the LC2 MLV HHCC mutant were visualized and the 
numbers of immature and mature particles in each set were determined.  The MP5 virus 
had 28/100 immature particles, the SR8 mutant had 57/100 immature particles, and the 
LC2 mutant had 38/100 immature particles. Therefore, the proteolytic processing defect 
observed by western blotting analysis did not result in any apparent morphological 
changes or shifts in maturation in the IN-mutant viruses. 
Real-Time PCR of Pol Mutants. In order to determine if the pol mutations had an effect 
on reverse transcription, D17 cells were infected with viruses containing the different Pol 
mutations; and 6 hours post-infection the infected cells were lysed, total cellular DNA 
was collected, and the amount of DNA was determined by a spectrophotometer.  One 
microgram of each of these DNA samples were subjected to real-time PCR analysis to 
detect products of reverse transcription.  A primer-probe set homologous to the R-U5 
region was used to detect minus-strand strong-stop DNA, and a primer-probe set 
homologous to the 3’ end of the neo gene was used to detect post-minus-strand DNA 
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transfer products of reverse transcription.  The data are presented in Table 4.  The 
amounts of PCR products for the SNV wild type RD136 were set to 100%.  The RT-
deficient YVNN mutant yielded very few reverse transcription products (0.2% and 0.1% 
of wild type R-U5 and neo products, respectively).  SR8, the SNV IN HHCC insertion 
mutant, exhibited 8.7% of wild-type R-U5 copy number and 9.4% of the wild-type neo 
copy number.  SR12, the IN catalytic core mutant, had 310% of wild-type R-U5 copy 
number and 240% of wild-type neo copy number.  Finally, the SNV RNase H mutant 
WZH73 had 23% of the wild-type R-U5 copy number, and 7% of the wild-type neo copy 
number.   
For the MLV Pol mutants, the amount of PCR products for wild type 
SNVgagMLVpol MP5 were set to 100%.  LC2, the HHCC insertion IN mutant, was 
shown to have 18% of wild-type MP5 R-U5 copy number, and 21% of MP5 wild-type 
neo copy number.  The SR13 IN catalytic core mutant was shown to have 19% of wild-
type R-U5 copy number, and 15% of wild-type neo copy number. 
 Because of differences between transfection efficiencies and differences in RT 
activities among the pol mutant viruses, all values for real-time PCR were normalized to 
virion RT activity to account for differences in the amount of processed RT in each virus 
and the amount of virus released from each producer cell line.  The results of the 
normalized amounts of reverse transcription products are also shown in Table 4.  
Following correction for RT activity, compared to the amounts of PCR products obtained 
from the wild type, SR8 HHCC insertion IN mutation had 80% of SNV wild type R-U5 
copy number, and 93% of SNV wild type neo copy number; and SR12 catalytic core IN 
mutation had 100% of SNV wild-type R-U5 copy number, and 56% of SNV wild type 
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neo copy number.  WZH73 had 8.5% of SNV wild type R-U5 copy number, and 2.6% of 
SNV wild-type neo copy number.  For the MLV Pol mutant viruses, LC2 HHCC 
insertion IN mutation had76% of MLV wild type R-U5 copy number and 89% of MLV 
wild type neo copy number, and SR13 catalytic core IN mutation had 49% of MLV wild 
type R-U5 copy number and 36% of MLV wild type neo copy number, following 
normalization to RT assay values.  Therefore, once the amount of RT activity from each 
sample was accounted for, the IN mutants were shown to be competent in both the 
initiation of minus-strand DNA synthesis and minus-strand DNA transfer. 
Complementation with SR7 D150E in Phenotypically mixed virions.  In order to 
determine the ability of the MLV RT-IN+ construct to co-assemble with and complement 
an RT+IN- gag-pol precursor, the SNVgag-D150E construct MLV (RT- IN+) was used to 
establish a cell line.  The cell line also expressed amphotropic MLV envelope and 
contained an integrated copy of an MLV vector (Fig. 1C).  These cells were co-
transfected with IN-RT+ gag-pol constructs with pSV-hygro.   Pools of hygro resistant 
cells for each mutant were obtained, and virus harvested from these pools was subjected 
to RT and titer assays.  The results are shown in Table 5.  For the SNV gag-pol 
expression vector RD136, the average titer in three independent sets of experiments was 
223 X 102 cfu/mL.    The SR8 HHCC IN insertion mutant produced a titer of 1.2 X 102 
cfu/mL (0.5% of wild-type), and the SR12 catalytic core IN- mutant produced a titer of 
1.2 X 102 cfu/mL (0.5% of wild-type).  The WZH73 RNase H mutant was produced a 
complemented titer of 5.3 X 102 cfu/mL, or 2.4% of SNV wild-type titer.  In order to 
correct for the amount of processed RT available in the complemented virions, and to 
account for differences in transfection efficiencies, the complemented titers were all 
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normalized to RT activity.  The normalized titers are shown in Table 5.  The SNV wild 
type vector RD136 titer did not change with normalization.  The SR8 HHCC IN insertion 
mutant had a normalized titer of 15 X 102, or 7% of wild-type titer.  The SR12 catalytic 
core IN- mutant had a normalized titer of 1.2 X 102 cfu/mL, 0.5% of wild type titer.  
WZH73 produced a normalized titer of 5.4 X 102, or 2.4% of wild type titer.  The SR12 
catalytic core IN- mutant and WZH73 RNase H mutant titers did not change significantly 
with normalization to RT activity, while the SR8 HHCC IN mutant titer increased 10-
fold.  The level of complementation relative to RT activity was better for the SR8 HHCC 
IN insertion mutant than in then SR12 catalytic core IN mutant, probably because of the 
processing defect seen in the SR8 HHCC IN mutant reduced the RT activity generated by 
the construct. 
For the SNVgag-MLVpol mutants, the MP5 wild type construct had a titer of 256 
X 102 cfu/mL, and the LC2 HHCC IN insertion mutant (RT+IN-) produced a 
complementation titer of 0.8 X 102 cfu/mL (0.3% of wild-type).  SR13 catalytic core IN 
mutant produced a titer of 0.1 X 102 cfu/mL (0.5% of wild-type).  As with the SNV Pol 
mutant viruses, these titers were normalized for RT activity.  The wild type MP5 titer did 
not change with normalization, and the LC2 HHCC IN (RT+IN-) insertion mutant had a 
normalized titer of 150 cfu/mL; this raised its relative wild type titer to 0.5%.  The SR13 
(RT+IN-) catalytic core mutant had a normalized titer of 6 cfu/mL; this lowered its 
relative wild type titer to 0.3%. 
These results show for the first time that SNVgagSNVpol and SNVgagMLVpol 
proteins can co-assemble and replicate together.  Complementation by MLV IN produced 
by IN+RT- constructs and MLV RT produced by the RT+IN- construct was as efficient as 
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complementation by SNV IN produced by IN+RT- constructs.   This suggests that the 
protein-protein contacts between the SNV and MLV reverse transcription complexes and 
the pre-integration complexes are similar in these two viruses.   
Complementation with SNV YVNN mutant in Phenotypically Mixed Virions. 
In order to determine the ability of an SNV RT-IN+ construct to co-assemble with and 
complement an RT+IN- gag-pol precursor, the SNVgag-YVNN construct (SNV RT-IN+) 
was used to establish a cell line.  The cell line also expressed amphotropic MLV envelope 
and contained an integrated copy of an MLV vector (Fig. 4A).  These cells were co-
transfected with IN-RT+ gag-pol constructs with pSVα3.6.  Pools of ouabain-resistant 
cells for each mutant were obtained, and virus harvested from these pools was subjected 
to RT and titer assays.  The results are shown in Table 6.  The SNV wild type RD136 
vector produced a titer of 120 X 102 cfu/mL.  The SR8 HHCC IN insertion mutant had no 
detectable titer, and it had an RT activity of 2% of wild type.  This suggests that the 
YVNN had a dominant negative effect on the SR8 vector, since this vector was able to 
complement the MLV RT (Table 5). The SR12 catalytic core IN mutant had a titer of 30 
cfu/mL (0.2%) and had 88% wild-type RT activity.  The WZH73 RNase H mutant, which 
produced an RT activity of 68% of wild-type,  produced a titer of 150 cfu/ml, or 1.3% of 
wild type titer.  When normalized to RT activity, the SR12 catalytic core IN mutant had a 
titer of 34 cfu/mL, or 0.3% wild type titer, and the WZH73 RNase H mutant had a titer of 
220 cfu/mL, or 1.8% wild type titer. 
 The results of the YVNN complementation with the MLV pol mutants are shown 
in Table 6.  The MP5 wild-type SNVgagMLVpol vector had a titer of 130 cfu/mL.  The 
LC2 HHCC IN insertion mutant had an RT activity that was 30% of wild type and 
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produced no detectable titer.  The SR13 IN substitution mutant had a RT activity that was 
140% of wild type and produced a titer of 60 cfu/mL, or 47% of the wild type.  Following 
correction for RT activity, the SR13 IN HHCC mutant produced a complementation titer 
of 120 cfu/mL, or 100% of wild type.    
First of all these results demonstrate that SNVgagSNVpol and SNVgagMLVpol 
proteins can complement each other and restore titer.  Second of all, the LC2 and SR8 IN 
HHCC insertion mutants were unable to complement, despite the fact that the LC2 
mutant had RT activity.  It was noted that the YVNN mutant, in addition to its RT defect, 
had a processing defect on western blot (data not shown).  The SR8 and LC2 HHCC 
insertion mutants also had processing defects; it is possible that because both Gag-Pol 
precursors had processing defects, they were unable to complement each other to restore 
virus titer.   
 
DISCUSSION 
 
Previously, it was shown that a chimeric SNVgagMLVpol vector could replicate 
with wild type efficiency as long as the vector RNA used was derived from MLV 
sequences (5).  This chimeric vector was utilized to investigate whether Pol polyproteins 
from two different species of virus, SNV and MLV, could be incorporated into the same 
virion and cooperate to complete one round of virus replication.  The results presented in 
this paper show for the first time that SNV and MLV Pol proteins can co-assemble 
together in the same virion, as long as the two polyproteins are synthesized with an 
SNVgag in the Gag-Pol molecule.  Furthermore, it was shown that two different species 
of Pol polyproteins could interact to complete reverse transcription and integration.  This 
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was shown definitively by the ability of an RT-deficient SNVgagMLVpol (RT-IN+) 
construct to be complemented by an IN-deficient SNVgagSNVpol  (RT+IN-) construct to 
complete viral replication.  Similarly, an RT-deficient SNVgagSNVpol (RT-IN+) was be 
rescued by an IN-deficient SNVgagMLVpol (RT+IN-).   
The level of complementation seen between the SNV RT+IN- constructs and the 
MLV RT-IN+ constructs was noted to be similar to the level of complementation seen 
between MLV RT+IN- and MLV RT-IN+ in these experiments (Tables 5 and 6).  These 
results showed that level of complementation of the MLV RT -IN+ vector were the same 
for SNV RT+IN- and MLV RT+IN-, indicating that SNV and MLV RT proteins can 
interact equally well with MLV IN. 
Thirdly, the nature of the mutation used to knock out IN function impacted the 
level of complementation seen in this system.  The HHCC IN insertion mutations used in 
this study resulted in processing defects that accounted for a decrease in the amount of 
RT available for reverse transcription.  The processing phenotype seen in both the MLV 
IN and SNV IN mutant viruses agrees with the phenotype seen by others for similar 
mutations in MLV IN (23).  The level of complementation was greater for the HHCC 
mutation than for the catalytic core substitution mutant following normalization for RT 
activity.  Because the HHCC IN insertion mutant had a processing defect, it produced 
less RT, and therefore its level of complementation was higher when corrected for RT 
activity.    
Complementation systems have been widely utilized to explore mechanisms and 
properties of reverse transcription.  Efficient complementation has been observed 
between MLV RT and MLV RH (12); this system showed wild-type interactions between 
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MLV RT-RH+ and MLV RT+RH- constructs.  In the system described here, 
complementation between the MLV RT-RH+ and the SNV RT+IN- was as efficient as 
between the MLV RT-IN+ and the SNV RT+RH-, indicating that complementation 
between IN and RT is as efficient as RT and RH.  The system utilized in this work 
differed from the previous investigation because the RT-IN+ cell lines were derived from 
pools of transfected cells rather than individual cell clones; this could have impacted the 
maximum amount of complementation that was observed as the study discussed above 
used an MLV RT-RH+ cell line that was derived from a single cell clone. 
Many aspects of integrase function have been investigated using trans-
complementation systems in HIV-1 and MLV.  Initially, these studies proved a direct role 
for IN during reverse transcription for both HIV-1 and MLV.  In HIV-1, the catalytic 
core of IN was dispensable for reverse transcription, while the HHCC motif was not (17, 
29); surprisingly, different results were found for MLV.  An MLV IN truncation mutant 
lacking the C-terminal domain of IN was shown to be defective in reverse transcription 
(11).  Our real-time PCR data indicate that MLV HHCC IN insertion mutants are able to 
initiate reverse transcription and mediate minus-strand DNA transfer as well as wild-type 
IN, once normalized to RT activity, which is in agreement with the data reported by 
others for MLV (17).  Our results showed no limitation of the SNV or MLV IN catalytic 
core mutants in RT activity or initiation of reverse transcription.  However, the SNV 
RNase H mutant WZH73 was somewhat deficient in the initiation of minus-strand DNA 
synthesis, as well as deficient in minus-strand DNA transfer.  This finding is similar to 
that found with MLV RNase H (14).  The SNV and MLV IN HHCC insertion mutants 
were deficient in RT activity, which correlated with a processing defect seen in these 
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mutants.  Therefore, our results do not definitively demonstrate a role for SNV or MLV 
IN during reverse transcription of MLV RNA; however, participation of these proteins in 
reverse transcription cannot be ruled out on the basis of these results. 
A second important finding of IN trans-complementation studies has been to 
demonstrate an interaction between different species of IN proteins.  In an HIV-1 system, 
an HIV-2 IN was not able to rescue HIV-1 reverse transcription; however, the HIV-2 IN 
was able to integrate HIV-1 cDNA once reverse transcription was completed (29).  Our 
results showed no difference in the ability of MLV IN to rescue reverse transcription or 
integration in an SNV or MLV RT+IN- construct.  This strongly suggests that several 
crucial RT-IN interactions are conserved between SNV and MLV.  These results indicate 
that protein interactions in the reverse transcription and pre-integration complexes for 
MLV and SNV are conserved, and that the individual proteins can interact with other 
distantly related retroviral proteins.  SNV and MLV Pol proteins contain have relatively 
low sequence homology (53%).  Despite the fact that SNV and MLV IN are very 
divergent in sequence, data by others suggest that the C-terminal portion of IN is 
involved the protein-protein interactions.  The C-terminal regions of IN encompassing 
residues 345-365 of MLV has nearly 100% sequence identity with residues 329-349 of 
SNV IN; this could comprise a region of IN that contains the crucial contacts that allow 
for the interchangeability of SNV and MLV IN.  This is of significance because it 
highlights a possible mechanism for evolution of new species of retroviruses, and perhaps 
viruses with increased pathogenecity or immune evasion for the host.   
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FIGURE LEGENDS 
 
Figure 1. A: Vectors used in study. MA, matrix, pX, protein X, CA, Capsid, NC, 
nucleocapsid, Pr, protease, RT, reverse transcriptase, IN, integrase.  Open box denotes 
SNV-derived sequences, while gray shading denotes MLV-derived sequences.  B: 
Experimental Protocols.  Gray shading denotes MLV-derived sequences. EM, electron 
microscopy, RT, reverse transcriptase. 
Figure 2.  A: MLV RT-IN+ cell line.  Gray shading denotes MLV-derived sequences, 
open boxes indicate SNV-derived sequences.  B: Protocol for Complementation. 
Figure 3.  Western Blot profile of Viruses harboring IN mutations. A: MP5, 
SNVgagMLVpol wild type virus. LC2, SNVgagMLVpol IN HHCC insertion mutant.  
SR13, SNVgagMLVpol IN D125A catalytic core mutant.  B: RD136, SNVgagSNVpol 
wild type virus.  SR8, SNVgagSNVpol IN HHCC insertion mutant, SR12, 
SNVgagSNVpol IN D109A catalytic core mutant.  Two bands are visible in both blots, 
p55-Gag, which represents unprocessed Gag protein, and p30 CA, which represents the 
processed capsid protein. 
Figure 4. A. SNV RT-IN+ cell line.  Gray shading denotes MLV-derived sequences and 
open boxes denote SNV-derived sequences.  B: Protocol for complementation of the 
SNV RT-IN+ with RT+IN- vectors. 
Appendix, Figure 1.  RD136, SNVgag-pol  wild type.  SR12, SNVgag-pol  IN D109A 
catalytic core mutant. 
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Table 1. Primers used to construct Pol mutants. 
 
 
Primer Name 
 
Primer Sequence 
Nerd136- 
4372 
5’-CTCAAGCAGAAGCCACCTTGTT-3’ 
D109A- 
SNVInfor 
5’-GGAACACTGGGAGGTGGCATTCACAGAAATGGTAAC AGC-3’ 
D109A- 
SNVInrev 
5’-GGCTGTTACCATTTCTGTGAATGCCACCTCCCAGTGTTC C-3’ 
Nerd136- 
5475C 
5’-AGGTCGGTACGCACAGTGGAGTT-3’ 
SNVgag- 
4421 
5’-CCACACCTGGTACACGGATGGAA-3’ 
D125A- 
MLVInfor 
5’-GGCACTCATTGGGAGATCGCATTCACCGAGATAAAGCCC GG-3’ 
D125A- 
MLVInrev 
5’-CCGGGCTTTATCTCGGTGAATGCGATCTCCCAATGAGTGCC- 3’ 
SNVgag- 
6060C 
5’-GTTGAACGCGCCATGTCAGTCTA-3’ 
IN-minus-5’ 5’-GATCCATGCATC-3’ 
 
IN-minus 3’ 5’-CATGGATCCATG-3’ 
 
MLV IN- 
linker5’ 
5’-AGCTGGTATACC-3’ 
MLV IN- 
linker3’ 
5’-AGCTGGTATACC-3’ 
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Table 3. Quantification of mature vs. immature virion particles in IN HHCC insertion mutants.
Virus # immature particles/ # mature particles 
MP5 28/72 
LC2 38/62 
SR8 57/43 
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Figure 3.
A. 
B. 
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Table 2.  Replication Properties of SNV and MLV Pol Mutants 
 
 
Real Time PCR of Reverse Transcription Products Vector Titer, 
cfu/mLa 
±S.E. 
Rel. RT 
Activitya 
±S.E. 
% wt 
# R-U5 
(%)±S.E. 
# neo  
(%)±S.E. 
% R-U5 
normalized 
for RT 
Activity±S.E. 
% Neo 
normalized 
for RT 
Activity±S.E.
SNV       
RD136 2.3±d 
1.3×103  
100 100 b 100 b 
 
100 100 
YVNN <1 4.9±4.8 0.2c 0.1 c 
 
4 2 
WZH73 2.3±2 272±333e 23±15 b 7±0.8 b 
 
8±5 2.6±0.4 
SR8 <1 10±6.6 8.7±4.5 b 9.4±5 b 
 
80±45 93±49 
SR12 <1 425±340 310±80a 240±44a 
 
72±19 56±10 
MLV       
MP5 6.6± 
0.6×103 
100 100a 100 100 100 
LC2 <1 23±9 18±5f 21±12 76±22 89±52 
 
SR13 <1 35±18 17±7a 13±9 49±19 36±25 
       
 
a Average of three independent experiments 
b Average of two independent experiements.  Each reaction was performed three times. 
c One experiment.  Each reaction was performed three times. 
d Six independent experiments. 
e One measurement out of three was significantly higher than the wild type.  The other  
two measurements were equivalent to wild type.  See Appendix for table of individual 
measurements of all mutants. 
f Average of two independent experiments 
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 Table 4.  Complementation of SNV and MLV Pol Phenotypically Mixed Virions Derived  
from the SNV-gag D150E Cell Linea 
 
 
Vectorb,c RT Activity, 
% wt 
±S.E. 
Titer, cfu/mL 
±S.E 
% WT 
Titer 
±S.E 
Titer 
Normalized 
for RT 
Activity 
±S.E 
Normalized 
titer, % 
WT 
±S.E 
SNV      
RD136 100 223±0.25×102 100 223×102 100 
WZH73 99±21 5.3±4 × 102 2.4 5.4×102 2.4 
SR8 8±4.5 1.2±0.6 × 102 0.5 1.5×103 7 
SR12 101±24 1.2±0.4 × 102 0.5 1.2×102 0.5 
      
MLV      
MP5 100 256±0.6 × 102 100 256×102 100 
LC2 55±9 0.8±0.3 × 102 0.3 1.5×102 0.5 
      
MP5 100 19±13 × 102 100 19×102 100 
SR13 170±56 0.1±.07 × 102 0.5 .06×102 0.3 
a Averages of 3 independent experiments are shown. 
b RD136, SNVgag-pol wild type. WZH73, SNVgag-pol RNase H D524N mutant. SR8, 
 SNVgag-pol IN HHCC insertion mutant. SR12, SNVgag-pol IN catalytic core mutant. 
c MP5, SNVgagMLVpol wild type. LC2, SNVgagMLVpol IN HHCC insertion mutant.  
SR13, SNVgagMLVpol IN D125A catalytic core mutant.
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Table 5. Complementation of SNV Pol Mutants in the SNVgag-YVNN Cell Line 
 
 
Vector RT Activity, 
% wt 
Titer, cfu/mL % wt titer Titer 
normalized 
for RT 
activity 
% Wild 
Type titer, 
normalized 
for RT 
RD136 100 120 × 102 100 120 ×102 100 
WZH73 68 1.5 × 102 1.3 2.2 × 102 1.8 
SR8 2 <1 - - - 
SR12 88 0.3 × 102 0.2 0.34 × 102 0.3 
      
MP5 100 1.3 × 102 100 130 100 
LC2 30 <1 - - - 
SR13 140 0.6 × 102 47 130 100 
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ABSTRACT 
 
We have identified a region near the C terminus of capsid (CA) of murine 
leukemia virus (MLV) that contains many charged residues.  This motif is conserved in 
various lengths in most MLV-like viruses.  One exception is that spleen necrosis virus 
(SNV) does not contain a well-defined domain of charged residues.  When 33 amino 
acids from the MLV motif were deleted to mimic SNV CA, the resulting mutant 
produced drastically reduced amounts of virions and the virions were non-infectious.  
Furthermore, these viruses had abnormal sizes, often contained punctate structures 
resembling those in the cell cytoplasm, and packaged both ribosomal and viral RNA.   
When 11 or 15 amino acids were deleted to modify the MLV CA to resemble 
those from other gammaretroviruses, the deletion mutants produced virions at levels 
comparable to the wild type virus and were able to complete one round of virus 
replication without detectable defects. We generated 10 more mutants that displayed 
either the wild-type or mutant phenotype.  The distribution of the wild type or mutant 
phenotype did not directly correlate with the number of amino acids deleted, suggesting 
that the function of the motif is not simply determined by its length but by its structure.  
Structural modeling of the wild-type and mutant proteins suggested that this region forms 
α-helices; thus, we termed this motif charged assembly helix.  This is the first description 
of the charged assembly helix motif in MLV CA and the demonstration of its role in virus 
budding and assembly.   
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INTRODUCTION 
 
All retroviruses encode at least the gag, pro, pol, and env genes, which are 
translated into polyproteins and subsequently cleaved into individual virion proteins (38).  
The gag gene products form the structure of the virions, pro gene products process the 
viral proteins, pol gene products carry out important enzymatic reactions, and env gene 
products serve as the viral surface envelope (38).  Although all four gene products are 
essential in the generation of wild-type, infectious virions, the gag gene product, Gag 
polyprotein, drives the formation of the virus particles.   When Gag polyproteins are 
expressed in host cells, they can form virus-like particles without other retroviral 
components such as pro, pol, or env gene products or viral RNA containing the retroviral 
packaging signals (35, 41).  Purified Gag polyproteins, or portions of the polyproteins, 
can also form virus-like particles in vitro (6, 7, 13, 19).  Together, these data indicate that 
Gag polyproteins are necessary and sufficient for the formation of the virus-like particles.  
 Gag polyproteins from all retroviruses contain at least three domains that are later 
cleaved by viral protease into mature proteins: matrix (MA), capsid (CA), and 
nucleocapsid (NC) (38).  Most retroviruses also contain other cleavage products that vary 
in size and in the location of the domain on the polyprotein.  For example, murine 
leukemia virus (MLV) Gag has an additional 12-kDa cleavage product termed p12; the 
p12 domain is located between MA and CA in the Gag polyprotein.  In human 
immunodeficiency virus type 1 (HIV-1), Gag polyproteins have three additional cleavage 
products, p2, p1, and p6.  The p2 domain is located between CA and NC whereas p1 and 
p6 are located C-terminal to NC in the Gag polyprotein (32).   
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Different domains of Gag polyproteins contain distinct signals to direct virus 
assembly and budding.  Signals in MA target Gag to the cell membrane, motifs in the NC 
domains mediate RNA binding, and motifs in CA and NC are important in the 
multimerization of Gag polyproteins (35, 38).  After formation of the virus-like particles, 
host cell factors recruited by the late domains, which are located at various positions in 
Gag of different viruses, interact with the cell membrane to allow the release of the viral 
particles (16).  During or soon after virus budding, viral proteases are activated and 
cleave the polyproteins into smaller proteins (35).  Upon protease cleavage, the virions 
undergo morphological changes and become mature particles (35).  The mature particle, 
and not immature particle, contains an electron-dense core, which can be identified 
during electron microscopy (EM) (38).    
CA is involved in multiple stages in the retroviral replication cycle. As a cleaved, 
mature viral protein, CA forms the condensed core of the mature virus particle and 
constitutes part of the reverse transcription complex in certain viruses (4, 14, 38).  As a 
part of the Gag polyprotein, CA plays a role in virus assembly.  This is supported by the 
genetic studies, in which mutations in CA often lead to assembly defects (15, 20, 35).  
However, the exact mechanism of CA’s involvement in virus assembly remains unclear.  
Structural analyses of CA from several viruses illustrate that these proteins consist of two 
α-helix-rich domains, N-terminal and C-terminal domain, connected by a flexible linker 
region (3, 18, 23, 24, 39).  The primary sequences of the CA from different retroviruses 
are divergent; the most conserved region in CA is located in the C-terminal domain 
(QX3EX7R), and is termed the major homology region (MHR) (41).  Mutations in this 
region often lead to defects in the viral replication cycle (2, 5, 10, 28).   
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The amino acid sequence at the C-terminal region of MLV CA has a stretch of 41 
amino acids rich in charged residues (Fig. 1A).  Of these 41 amino acids, 33 are charged 
residues with similar numbers of acidic and basic residues (16 and 17, respectively).  The 
function of this motif rich in charged residues is unknown.  In this report, we examined 
the effects of mutations on this motif, and found that disruption of this motif could result 
in assembly defects.  Furthermore, mutants lacking functional motifs generated virions 
with highly varied particle sizes and packaged both ribosomal and viral RNAs.  These 
results indicated that this motif rich in charged residues is an important region in the 
assembly of MLV particles.        
 
MATERIALS AND METHODS 
 
Plasmids and construction of mutant gag-pol expression constructs.  All 
vectors were constructed using standard cloning procedures (34).  Mutations were 
generated using overlapping PCR and cloning of the resulting DNA fragments into the 
MLV-based gag-pol expression construct pWZH30 (42), a generous gift from Vinay 
Pathak.  Plasmid pWZH30 is derived from pLGPS (30), which expresses gag-pol from a 
truncated 5’ long terminal repeat (LTR) and does not contain the packaging signal or the 
3’ LTR.  The overall structures of the mutant gag-pol constructs were determined by 
restriction enzyme analyses; the portions of DNA generated by PCR were further 
characterized by DNA sequencing.  Detailed cloning procedures are available upon 
request.  Plasmids pEW22U and pEW22D also contained an additional H114R mutation 
in the capsid region; this mutation was located 108 amino acids N-terminal to the motif 
described in this report.   
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Plasmid pSV-a-MLV-env expresses amphotropic MLV env (27).  MLV-based 
vector pSR2 (8) contains all the cis-acting elements essential for replication; pSR2 does 
not express viral proteins, but expresses hygromycin phosphotransferase B gene (hygro), 
which confers resistance to hygromycin (22).  pSR2 also has two modified LTRs, both of 
which contain a copy of the green fluorescent protein gene.      
Cell culture, DNA transfection, virus propagation, and virus infection.  D17 
cells are dog osteosarcoma cells permissive to amphotropic MLV infection (33); 293T 
cells are human embryonic kidney cells (12).  Both cell lines were maintained at 37oC 
with 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with serum and 
antibiotics (8, 12).  DNA transfection was performed by the calcium phosphate 
precipitation method (34) using the CalPhos transfection kit (ClonTech) or MBS 
transfection kit (Stratagene) with a mixture of DNA containing the gag-pol expression 
construct, pSR2, and pSV-a-MLV-env at a 2:2:1 weight ratio.   
Ten-fold dilutions of the viruses were used to infect D17 cells in the presence of 
Polybrene (50 µg/ml, final concentration).  Infected cells were placed on hygromycin 
selection at a final concentration of 120 µg/ml, and virus titers were determined by the 
numbers of hygromycin-resistant colonies.  In general, viral titers measured in these 
assays agreed with the reverse transcriptase (RT) activities.  The virus titers presented 
were not standardized to RT activities because some of the mutants had low RT 
activities, which were not significantly higher than background.     
RT Assay, western analyses, and EM analyses.   Viruses were harvested and 
concentrated by centrifugation at 25,000 rpm for 90 min at 4oC using a Surespin 630 
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rotor (Sorvall) in a Discovery 100S ultracentrifuge (Sorvall).  RT activities of the viral 
samples were determined using standard procedures (8, 36).  Proteins from cell lysates or 
virus lysates were examined by western blotting analyses performed using standard 
procedures (34).  Polyclonal rabbit anti-MLV-CA and anti-MLV-MA antibodies were 
kind gifts from the AIDS Vaccine Program (SAIC, NCI-Frederick).   
For EM analyses, transfected 293T cells were washed with phosphate-buffered 
saline, pelleted by low-speed centrifugation, and fixed in 2% glutaraldehyde in 
cacodylate buffer (0.1 M, pH 7.4).  EM analyses were performed as previously described 
(37) (Hitachi H7000) and images were captured by a digital camera system (Gatan).       
RNA analyses. To examine the RNA encapsidated in wild type and mutant 
viruses, gag-pol expression constructs were used to separately transfect SR2-293T cells.  
SR2-293T cells are 293T cells containing integrated SR2 proviruses.  These cells were 
generated by infecting 293T cells with SR2-containing virions, subjecting the infected 
cells to hygromycin selection, and pooling the resulting hygromycin-resistant cell 
colonies.  Cell-free viruses were harvested from transfected SR2-293T cells, virion RNA 
were isolated using previously described protocols (17).  The amounts of encapsidated 
SR2 RNA and ribosomal RNA were determined using quantitative real-time RT-PCR 
(ABI 7700 sequence detector).  Primers and probe sequences derived from hygro were 
used to detect SR2 vector RNA.  The primers and probe have the following sequences: 5′ 
ACGAGGTCGCCAACATCTTC 3′ (primer), 5′ AGCGCGTCTGCTGCTCC 3′ (primer), 
and 5′ FAMTCTGGAGGCCGTGGTTGGCTTGTATAMRA 3′ (probe).  Primers and probe 
derived from 18S ribosomal RNA gene were used to detect 18S ribosomal RNA.  The 
primers and probe have the following sequences: 5′ GCCGCTAGAGGTGAAATTCTTG 
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3′ (primer), 5′ CATTCTTGGCAAATGCTTTCG 3′ (primer), and 5′ 
FAMACCGGCGCAAGACGGACCAGATAMRA 3′ (probe).  RNA transcripts containing 
hygro sequences and purified rRNAs were used as templates to generate standard curves 
in the real-time RT-PCR for SR2 and rRNA detection, respectively.  RNA isolated from 
mock-transfected samples was used as negative control.      
 
 
RESULTS 
 
A motif rich in charged residues is conserved in the CA domain of most 
gammaretroviruses.  To determine whether the motif rich in charged residues is unique 
to MLV CA, the primary amino acid sequences of CA from multiple retroviruses were 
compared.  Most of the gammaretroviruses have similar motifs, albeit with different 
lengths.  A notable exception is spleen necrosis virus, which does not have a region with 
many charged residues in its CA (Fig. 1B).  Several viruses, including gibbon ape 
leukemia virus (GaLV), have motifs that are 11 amino acids shorter than that of MLV.  
Rat leukemia virus (RaLV) and feline leukemia virus (FeLV) both have motifs that are 15 
amino acids shorter than that of MLV (Fig. 1B).  All of the motifs rich in charged 
residues have nearly balanced numbers of acidic and basic residues.   
We also examined the primary sequences of several other groups of more distant 
retroviruses and found that the CA proteins of these viruses do not have motifs rich in 
charged residues at the C-terminal region of their CA and sequences between CA-NC 
(not shown).  These viruses include Rous sarcoma virus (RSV), an alpharetrovirus; 
Mason-Pfizer monkey virus, a betaretrovirus; human T cell leukemia virus type 1, a 
deltaretrovirus; and human immunodeficiency virus type 1 (HIV-1), a lentivirus.   
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The motif rich in charged residues is essential for efficient MLV replication 
and assembly.  To test whether this motif is essential for MLV replication and to 
examine its the possible roles, we constructed and characterized a mutant containing a 
large deletion that encompassed almost the entire motif.  Plasmid pSR33 was derived 
from the MLV gag-pol expression construct pWZH30 (42) and contained a 33-amino-
acid deletion in the motif (Fig. 2A).  To examine the phenotype of pSR33, we used the 
following protocols.  The MLV gag-pol expression construct pWZH30 or pSR33 was 
introduced into 293T cells by transfection along with pSV-a-MLV-env (27) and pSR2 
(8).  pSV-a-MLV-env expresses amphotropic MLV env.  pSR2 is an MLV-based vector 
that does not express gag-pol or env, but instead expresses hygro (22), which confers 
resistance to hygromycin.  Supernatants were harvested from the transfected 293T cells, a 
portion of the sample was used to infect target D17 cells to determine the virus titer, and 
the other portion was subjected to biochemical analyses.  Infected D17 cells were 
subjected to hygromycin selection and the SR2 virus titers were determined by the 
number of hygromycin-resistant cell colonies.  The amounts and properties of the viral 
protein released in the cell-free supernatants were determined by western blotting 
analyses and RT assays, and the morphology of the released virions was examined by 
EM.    
Viral titers generated from six sets of independent experiments are summarized in 
Table 1.  Supernatants from pWZH30-transfected cells on average generated a titer of 6.0 
× 103 hygromycin-resistant colony forming units (CFU)/ml.  However, supernatants 
harvested from pSR33-transfected cells did not generate detectable titers in any of the six 
experiments.       
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Representative analyses of viral proteins from transfected cells and harvested 
supernatants are shown in Fig. 3.  Virions generated from pWZH30-transfected cells are 
referred to as wild type.  Virions were released from pSR33-transfected cells at an 
approximately 30- to 100-fold reduced level compared with that of wild type (Fig. 3A 
and data not shown).  Western analyses also showed that Gag polyproteins expressed by 
pSR33 were mostly processed; CA from pSR33-derived virions migrated faster than CA 
from wild-type viruses, consistent with the 33-amino-acid deletion, whereas MA from 
both viruses had the same mobility.  Western analyses from transfected cell lysates 
showed that Gag polyproteins were expressed in pWZH30- and pSR33-transfected cells 
at similar levels (Fig. 3B), indicating that the 33-amino-acid deletion did not significantly 
affect the amount of Gag polyprotein expressed in the transfected cells.  Therefore, 
viruses generated from pSR33-transfected cells had a defect in virus assembly and/or 
release.   
To examine the morphology of the viruses generated from the pWZH30- or 
pSR33-transfected cells, EM analyses were performed.  These analyses indicated that 
pSR33-derived viruses differed from wild-type viruses in both size and morphology.   
Representative images of the wild-type and pSR33-derived virions are shown in Fig. 5A-
D; all of these images are shown with the same magnification.  Wild-type virions were 
close to 100 nm in diameter, and both immature particles and mature particles with 
condensed cores were observed (Fig. 4A and data not shown).  In contrast, pSR33-
derived virions were often much larger than 100 nm, and all appeared to be immature 
(Fig. 4 B-D and data not shown).  In addition, punctate structures similar to those in the 
cell cytoplasm were observed in these virions.  Virions with a wide range of particle sizes 
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containing punctate structures were observed only in pSR33-transfected cells, not in 
untransfected cells or pWZH30-transfected cells (data not shown).    
To further quantify the distributions of virion particle sizes, we measured the sizes 
of 100 wild-type virions and 100 pSR33-derived virions (Table 2).  The particle sizes of 
the wild-type virions were tightly clustered; of the 100 virions, 98 were 90-130 nm in 
diameter.  In contrast, the particle sizes of pSR33-derived virions were distributed 
through a wide range.  Of the 100 pSR33-derived virions, only 31 were 90-130 nm in 
diameter; the other 69 viral particles were smaller or larger than this size range, with 
some viruses more than 400 nm in diameter.   
The electron micrographs in Fig. 4C and D captured the images of pSR33-derived 
viruses in the process of budding out of the cells, and the contents of the mutant virions 
bear a striking resemblance to the cytoplasm.  This observation led us to examine the 
RNA content of pSR33-derived virions.  To avoid the potential complication caused by 
contamination of transfected MLV vector pSR2 DNA, we used 293T cells containing 
integrated SR2 proviruses (referred to as SR2-293T cells) in these experiments.  SR2-
293T cells were transiently transfected with pWZH30 or pSR33, and cell-free viruses 
were harvested.  For each virus sample, an aliquot was used to isolate RNA and the other 
aliquot was used to generate lysates for western analyses.  The amounts of viruses in 
these samples were determined by measuring the quantity of MA in cell-free viral lysates 
using western analyses on serially diluted lysates.  The amounts of SR2 RNA and 18S 
ribosomal RNA in each sample were determined using quantitative real-time RT-PCR 
with probes and primers derived from hygro and 18S ribosomal RNA sequences, 
respectively.  Data summarized from three sets of independent experiments are shown in 
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Fig. 5A and B.  Virions derived from pSR33 encapsidated SR2 RNA at an efficiency of 
79% of the wild-type virions.  More strikingly, pSR33-derived virions packaged 3100% 
of the 18S ribosomal RNA relative to wild-type virions.  To ensure that the RNA 
measured in these experiments was derived from virions rather than from cellular debris, 
we have also measured the amounts of SR2 RNA and 18S ribosomal RNA in the 
supernatants from mock-transfected cells, and compared with the amounts of RNA 
detected in the same volume of supernatant from pWZH30-transfected cells.  In two 
independent experiments, we were not able to detect SR2 RNA (less than 0.01% of the 
signals from wild-type virus) and we detected low amounts of ribosomal RNA (an 
average of 1.6% of the amount detected from wild-type virus controls) in the supernatant 
from mock-transfected.  These results confirmed that pSR33-derived virions contained 
ribosomal RNA; therefore, the punctate structures inside the virions observed by EM 
were most likely ribosomes.   
Taken together, these data indicate that deletion of the motif rich in charged 
reidues could result in defects in virus assembly, which would affect both the numbers of 
virions released from the cells and the properties of the released viral particles.   
The MLV motif rich in charged residues can tolerate relatively large 
deletions: phenotypes of mutants with motifs mimicking those of other 
gammaretroviruses.  As shown in Fig. 1B, many gammaretroviruses have shorter motifs 
compared with that of MLV.  To test whether a shorter motif can function in the context 
of MLV, we generated three MLV-based mutants containing motifs that were the same 
lengths as those from GaLV, RaLV, and FeLV.  These mutants (pSR11, pSR15, and 
pFeEW) contained 11-, 15-, and 15-amino-acid deletions, respectively (Fig. 2B).  The 
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phenotypes of these mutants were examined using the same protocol as described above.  
Western analyses of the supernatants from cells transfected with these plasmids indicated 
that the levels of virions released and the processing of Gag polyproteins were similar to 
those of the wild type (Fig. 6A).  Virions from these deletion mutants were infectious, 
generating titers similar to those from wild-type virus (Table 1).  EM analyses indicated 
that these virions had the wild-type virion morphology (data not shown).  These data 
established that these deletion mutants were phenotypically similar to wild-type viruses.  
Therefore, the functional requirement of the motif rich in charged residues could be 
fulfilled by shorter-than-wild-type sequences.     
The function of the motif rich in charged residues is not solely determined by 
its length and primary sequences.  Because the virions generated from pSR11-, pSR15-
, and pFeEW-transfected cells were similar to wild-type viruses in all aspects examined, 
we questioned whether the MLV motif could tolerate even larger deletions.  To 
investigate this question, we generated mutants that contained 17-, 19-, and 21-amino-
acid deletions in the motif rich in charged residues (pEW17, pEW19, and pEW21, 
respectively) (Fig. 2C).  To maintain the balance in acidic and basic residues, we used 
pSR15 as a template and deleted equal numbers of acidic and basic residues in these 
mutants.  The phenotypes of these constructs were examined using the protocols 
described above.  Western analyses indicated that pEW17- and pEW21-transfected cells 
released very little virus in their supernatants (Fig. 6B).  In contrast, pEW19-transfected 
cells released amounts of virus similar to those of the wild type into their supernatants 
(Fig. 6B); furthermore, the Gag polyproteins from pEW19-generated viruses were 
processed similarly to the wild-type viruses (Fig. 6B).  The reduction of the virion 
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production in pEW17- and pEW21-transfected cells was not due to lack of Gag 
expression, as indicated by western analyses of the cell lysates (Fig. 7C).  EM studies of 
these samples revealed that viruses generated from pEW17 resembled those from pSR33, 
whereas pEW19 generated virions with morphology similar to that of wild-type viruses 
(data not shown).  In four to six sets of independent infection experiments, pEW17 and 
pEW21 did not generate detectable titers; however, pEW19 and pWZH30 generated 
similar titers (Table 1).  Phenotypically wild-type virions were generated by pEW19 but 
not by pEW17, which contained a smaller deletion.  This result indicates that the length 
of the primary sequence is not a sufficient criterion for predicting the function of the 
mutant motif and suggests that a secondary or tertiary structure is important to the 
function of the motif rich in charged residues.   
Testing the hypothesis that the MLV motif rich in charged residues forms a 
functionally important α-helical structure.  Deletion analyses implied a periodicity to 
the correlation between the numbers of amino acids deleted and the phenotypes of the 
resulting mutants.  For example, deletion of 11, 15, or 19 amino acids resulted in 
functional proteins, but deletion of 17 or 21 amino acids did not.  The differences in the 
numbers of amino acids among pSR11, pSR15, and pEW19 are four and eight, which 
approximate one and two complete turns in α helices, respectively.  In addition, analyses 
of the primary sequences of the MLV motif indicate that this region may form an α-
helical structure (Chou-Fasman prediction, PepPlot, and PeptideStructure, GCG program, 
University of Wisconsin).  We hypothesized that the MLV motif forms an α-helical 
structure and that maintenance of the overall structure and preservation of the helical 
phases are important to the function of this motif.  We also hypothesized that deletion of 
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one or more complete turns of the α-helices can allow the preservation of the structure 
and can lead to the production of phenotypically wild-type virions, whereas deletions of 
incomplete turns could drastically alter the properties of the α-helices and could result in 
phenotypically altered virions similar to those generated by pSR33.  To test this 
hypothesis, we generated additional mutants and examined their phenotypes by using the 
same protocols as described above.   
A 13-amino-acid deletion should delete approximately 3.6 turns of the α-helices 
and should result in the formation of phenotypically altered viruses.  Similarly, deletion 
of 20 amino acids (5.6 turns) should also result in an altered phenotype.  Therefore, we 
generated pEW13 and pEW20 containing 13- and 20-amino-acid deletions in the motif, 
respectively (Fig. 2D), and we examined their properties.  As predicted, western analyses 
indicated that these two mutants released drastically reduced levels of virions (Fig. 7A), 
and these virions generated titers less than 1 CFU/ml in two to five independent 
experiments (Table 1).  Western analyses of cell lysates indicated that Gag polyproteins 
were expressed in pEW13- and pEW20-transfected cells (Fig. 7B).      
Deletion of 18 and 22 amino acids of the motif should remove 5 and 6.1 turns of 
the α-helices, respectively, which should result in functional motifs.  Two 18-amino-acid 
deletion mutants were generated based on pEW17: one (pEW18E) had an acidic residue 
deleted; the other (pEW18R), a basic residue deleted (Fig. 2D).  Two 22-amino-acid 
deletion mutants were also generated based on pEW21: one (pEW22U) had a glutamic 
acid deleted and the other (pEW22D) had a histidine deleted (Fig. 2D).  Our results 
indicated that all four of these mutants had wild-type phenotypes in the amounts of virus 
released (Fig. 7A) and generated infectious viruses with titers similar to those from wild-
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type virus (Table 1).  These data also demonstrated that we were able to restore the 
infectivity of the virions by deleting one amino acid in the motif from the two parental 
constructs pEW17 and pEW21, which had generated non-infectious virions with mutant 
phenotypes.  Different numbers of acidic and basic residues were deleted in pEW18E and 
EW18R.  In pEW18R, 8 acidic and 8 basic residues were deleted; whereas in pEW18E, 7 
acidic and 9 basic residues were deleted.  Since both constructs generated infectious 
virions, these data suggested that the motif could tolerate minor fluctuations in the 
numbers of charged residues.  pEW22U and pEW22D also contained an additional 
mutation elsewhere in the capsid region (H114R).  This mutation probably did not affect 
capsid function, since viruses derived from these two plasmids had the wild-type 
phenotype.     
We also hypothesized that the individual amino acids may not affect the function 
of the motif as much as the maintenance of the helical phases.  We postulated that the 
mutant phenotype of pEW17-derived virions was caused by alteration of the helical phase 
and not by the loss of charged residues.  To test this hypothesis, we generated pEW15-
res, in which two alanines were inserted into pEW17 to restore the phase of the helices 
(Fig. 2D).  Western analyses and viral titers data indicated that pEW15-res-derived 
viruses had a wild-type phenotype (Fig. 7A, Table 1).    
Taken together, these data strongly support the idea that the MLV motif rich in 
charged residues forms an α-helical structure; this structure and the phases of the helices 
play important roles during virus assembly.   
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DISCUSSION 
 
In this report, we describe a novel motif in MLV CA that is rich in charged 
residues, affects virus assembly, and most likely forms a helical structure.  Thus, we 
termed this motif the charged assembly helix.  Many deletions in this motif cause an 
assembly defect with a new phenotype, i.e., virions with a wide range of particle sizes 
and contents that morphologically resemble the cell cytoplasm; in addition, these virions 
package both ribosomal and viral RNAs.  Virus with the charged assembly helix motif 
mutant phenotype exhibits drastically reduced particle production and even more greatly 
reduced infectivity.  We were able to capture EM images with viruses budding out of the 
cells (Fig. 4C and D).  However, the charged assembly helix mutant phenotype is distinct 
from the late-domain mutants that have virions tethered on the cell surface or viral 
particles connected to one another via uncleaved membranes (16, 21, 40).   
In a previous study, MLV NC mutants that could not efficiently package viral 
RNA were shown to package ribosomes (31).  The phenotype of the charged assembly 
helix mutants differs from that of the NC mutants in two aspects: the packaging of both 
ribosomal and viral RNA, and the widely varied particle sizes.  At least two possibilities 
can explain why charged assembly helix mutants but not NC mutants can package both 
ribosomal and viral RNA.  One possibility is that particle sizes play a critical role in the 
encapsidation of both types of RNA.  Compared with a 100-nm-diameter virion, virions 
with a 200-, 300-, or 400-nm diameter have 8, 27, and 64 times more volume in the 
particle, respectively.  The larger particles in charged assembly helix mutants might 
simply have more volume in which to accommodate both ribosomal and viral RNAs, 
whereas the 100-nm-diameter NC mutants or wild-type viruses do not.  The other 
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possibility is that the charged assembly helix mutants have lost a function(s) that prevents 
the incorporation of ribosomal RNA into the virion.  It was previously proposed that one 
of the roles of NC in wild-type viruses is to exclude ribosomes (31).  It is possible that 
Gag-RNA interaction has two distinct functions: to specifically package viral RNA, and 
to exclude ribosomes and possibly other cytoplasmic elements.  NC mutants might have 
lost both functions, whereas the charged assembly helix mutants have lost only the ability 
to exclude ribosomes and other elements.  Further studies will be needed to distinguish 
these possibilities.     
 Wild-type MLV virions are fairly uniform in size (Table 2), indicating that Gag 
multimerization is a regulated event.  One of the most striking features of the charged 
assembly helix mutant phenotype is the wide range of virion particle size distribution, 
indicating defects in this regulation.  In the MLV Gag polyprotein, CA and NC are 
immediately adjacent to each other and the charged assembly helix motif is located near 
their junction.  Substitution mutations in the CA-NC junction in MLV can cause defects 
in virus assembly (A. Rein, personal communication).  In some retroviruses, CA and NC 
are separated by other cleavage products, e.g., spacer peptides (SP) for RSV and p2 for 
HIV-1 (32).  Extensive mutational analyses revealed that the RSV CA-SP region is 
critical in the regulation of virion particle sizes; deletions in this region caused the 
formation of virions with heterogeneous sizes (26).  In HIV-1, mutations in p2 have been 
shown to cause assembly defects that generate virions with heterogeneous sizes and 
aberrant morphology (25).  Interestingly, the CA-p2 junction was proposed to be an α-
helical structure that is crucial for virus assembly (1).  Together with data from this 
report, these results suggest that the regions near CA-NC junctions are important in virus 
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assembly and particle size regulation in many retroviruses.  An intriguing possibility is 
that the charged assembly helix motif, SP, and p2 fulfill similar functions during 
retroviral assembly.      
 Structural studies of the C-terminal domain of HIV-1 CA revealed the presence of 
four α-helices; these helices play critical roles in maintaining the overall globular 
structure of the region as well as promoting CA-CA dimerization (18).  However, the 
structure of the last 11 amino acids of HIV-1 CA and the putative α-helix in p2 is 
currently unknown, and their roles in Gag-Gag interactions during assembly are not 
determined.  Although NMR studies were performed on peptides derived from MLV 
MHR (9); similar to HIV-1, the structure of the very C-terminus of MLV CA, including 
the charged assembly helix motif, remains unknown.  We performed molecular modeling 
to simulate the putative structure of the MLV charged assembly helix motif (Fig. 8).  The 
charge distribution in the wild-type motif was such that positively and negatively charged 
bands (shown in blue and red, respectively) were formed; in addition, a basic-residue 
cluster and a neutral cluster (shown in white) were located near the C terminus of CA.  
We observed that mutants with deletions of complete α-helical turns had the wild-type 
phenotypes, whereas mutants with deletions of incomplete turns, which drastically altered 
the helical phases, had the mutant phenotype.  The effects of deleting incomplete turns 
can be visualized in the modeled structures.  For example, in pSR11 and pEW18E, the 
basic clusters and neutral clusters near the C terminus of CA were oriented in a direction 
similar to that of the wild type.  In contrast, in pEW13 and pEW17, the basic clusters and 
neutral clusters were oriented drastically differently than that of the wild type.  The 
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alteration of the helical phases probably changed the property of the overall structure and 
thus interfered with the charged assembly helix function.   
Currently, we do not know how this putative α-helical structure affects MLV 
assembly.  It is possible that protein-protein interactions mediated by the charged 
assembly helix motif facilitates and regulates virus assembly.  The charged assembly 
helix may interact with other domain(s) in Gag, a cellular factor(s), or other charged 
assembly helix motifs in other Gag molecules.  It is also possible that the charged 
assembly helix serves as a structural element to orient NC during Gag-Gag interactions, 
although we consider this hypothesis less likely.  Analyses of HIV-1 NC structure 
indicate that the regions flanking the Cys-His boxes, including the region immediately 
adjacent to the α-helical structure, are very flexible (11).  Given this flexibility, it is 
likely that NC could compensate for some structural variations and would not have such a 
stringent requirement on the phases of the α-helices in this motif.  Of the other three 
aforementioned possibilities on the protein-protein interactions involving the charged 
assembly helix motif, we favor the hypothesis that intermolecular interactions among the 
charged assembly helix motifs facilitate the Gag multimerization process.  We find this 
hypothesis attractive because of the alternating positively and negatively charged bands 
on the proposed α-helices.  In addition, cross-linking experiments indicated that the very 
C-termini of the MLV CA domains are in close proximity with one another in immature 
virions (29).  This observation is in agreement with the possibility that charged assembly 
helix motifs from different Gag polyproteins interact with one another.  Studies are 
underway to probe the structure of the proposed α-helices and their relation to the 
function of the charged assembly helix motif in MLV CA.    
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Table 1.  Virus titers generated by gag-pol expression constructs with wild-type or 
mutant motifs  
 
Construct Viral titer (× 103)* 
pWZH30 6.0 ± 2.1 7.5 ± 1.9 
pSR33 <0.001 ND 
pSR11 2.5 ± 1.7 ND 
pSR15 10.0 ± 8.0 ND 
pFeEW 12.3 ± 11.4 ND 
pEW17 <0.001 ND 
pEW19 7.3 ± 6.4 ND 
pEW21 <0.001 ND 
pEW13 ND <0.001 
pEW15-res ND 10.8 ± 5.1 
pEW18E ND 7.0 ± 3.9 
pEW18R ND 3.9 ± 2.8 
pEW20 ND <0.001 
pEW22U ND 4.5 ± 2.4 
pEW22D ND 6.8 ± 1.6 
 
*Viral titer is shown as CFU/ml (mean ± SE).  The data from the left- and right-hand 
columns were generated from four to six and two to five sets of independent 
experiments, respectively.  ND, not determined. 
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Table 2.  Distribution of particle sizes from pWZH30- and pSR33-derived virions  
 
Particle diameter (nm) 
<100  100-150  150-200 200-250 250-300 30
Construct <90 90-100 100-110 110-120 120-130 130-140 140-150
pWZH30 0 10  32 41 15 1 1  0 0 0 
pSR33 5 8  5 10 8 7 6  17 21 6 
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FIGURE LEGENDS 
Fig. 1.  Location and sequence of the motif rich in charged residues.  (A) Location and 
sequence of the motif in MLV.  Amino acids between the motif and NC are underlined.  
MHR: major homology region.  (B) Comparison of sequences in the motif among several 
gammaretroviruses.  BaEV, baboon endogenous virus; GaLV, gibbon ape leukemia virus; 
KoRV, Phascolarctos cinereus (koala) retrovirus; MDEV, Mus dunni endogenous virus; 
PERV-A, porcine endogenous virus class A; PERV-B, porcine endogenous virus class B; 
RaLV, rat leukemia virus; FeLV-A, feline leukemia virus subgroup A; SNV, spleen 
necrosis virus.  Acidic and basic residues are shown in red and blue, respectively.     
 
Fig. 2.  Amino acid sequences of the motif rich in charged residues in wild-type and 
mutant gag-pol expression constructs.  ∆EW, the numbers of amino acids deleted.   
 
Fig. 3.  Characterization of pWZH30- and pSR33-transfected cells and virions derived 
from these cells.  (A) Western analyses of cell-free virions.  (B) Western analyses of cell 
lysates.  Lanes labeled SR2, supernatants or cell lysates from cells transfected with pSR2 
and pSV-a-MLV-env; other lane labels, supernatants or cell lysates from cells transfected 
with the indicated gag-pol expression construct, plus pSR2 vector and pSV-a-MLV-env.  
Both anti-MLV CA and anti-MLV MA antibodies were used for the detection of virion 
lysates, whereas only anti-MLV CA antibody was used to detect cell lysates.  The larger 
molecular weight bands (near the 79 kDa marker) detected in the SR33 virion lysates are 
probably caused by incomplete processing.  A wide smear (between 30 to 40 kDa) is 
present in the cell lysate analyses, which is presumably background created by 
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nonspecific antibody binding.  The migration of molecular size standards (in kilodaltons) 
and Gag, CA and MA is shown.   
 
Fig. 4.  Electron micrographs of pWZH30-derived virions (A) and pSR33-derived virions 
(B, C, and D).  All four micrographs are shown in the same magnification, with the 100-
nm bar indicated at the bottom of the graphs.   
 
Fig. 5.  Comparison of the RNA contents in pWZH30- and pSR33-derived virions.  (A) 
Virion associated SR2 RNA.  (B) Virion associated 18S ribosomal RNA.  Western 
analyses were performed to estimate the amounts of virions, and RNAs from the same 
amount of pWZH30- and pSR33-derived virions were compared.  RNAs from pWZH30-
derived virions were set as 100%.  Data from three independent experiments are shown 
as mean ± SE.    
 
Fig. 6.  Western analyses of the wild type and deletion mutants.  (A and B) Western 
analysis of cell-free virions.  (C) Western analysis of cell lysates.  The lane labels, 
antibodies used, and explanations are the same as in Fig. 3.  The migration of molecular 
size standards (in kilodaltons) and Gag, CA, and MA is shown.   
 
Fig. 7.  Western analyses of mutants generated to test the proposed α-helical structure.  
(A) Western analysis of cell-free virions.  (B) Western analysis of cell lysates.   The lane 
labels, antibodies used, and explanations are the same as in Fig. 3.  The migration of 
molecular size standards (in kilodaltons) and Gag, CA, and MA is shown.   
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Fig. 8.  Space-filling models of the predicted helical structure of the wild type and mutant 
MLV charged assembly helix.   N termini are located on the left.  Amino acids are 
colored by charge: blue, positive; red, negative; and white, neutral.  The wild-type 
charged assembly helix (labeled MLV) is shown in the center, two functional 
mutants (labeled pSR11 and pEW18E) are located at the left-hand side, and the 
two nonfunctional mutants (labeled pEW13 and pEW17) are located at the right-
hand side.  The basic clusters and neutral clusters near the C terminus of CA were 
oriented in the same direction in wild type and the two functional mutants.  In 
contrast, the basic clusters and neutral clusters were oriented drastically 
differently than that of the wild type in the two nonfunctional mutants.   
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DISCUSSION 
 The retroviridae are a complex family of viruses that exert a significant impact on 
global ecology and human health.  Through the process of reverse transcription, 
retroviruses gain permanent residence in the genome of any host they infect (28).  Once 
established in the infected cell, they can produce progeny virions that can infect other 
cells.  During this process, retroviruses capture and activate cellular oncogenes, which 
can cause cancer and leukemia in the host, or they can themselves cause outright disease.  
The retrovirus with the biggest impact on human health and biology is HIV-1.  HIV-1 
infections started emerging in Africa and Haiti in the 1970’s, and in the United States in 
the early 1980’s; in less than half a century, HIV-1 has swept the world in all continents, 
causing a global health crisis (12).  Africa’s public health infrastructure is poorly 
equipped to contain its epidemic (9) and other nations are not faring much better.  Even 
in the United States and Europe where the infection prevalence is the lowest in the world, 
infection rates are rising (30), and current therapies are not able to cure the disease.  
There is increasing viral resistance to current HAART therapy (22, 26) that will at some 
point render the drugs currently available obselete. 
 Several advances in our understanding of retroviruses have lead to therapies that 
preserve a high quality of life for people afflicted with AIDS.  Elucidation of the 
mechanisms of reverse transcription allowed development of nucleoside analogs to 
effectively halt HIV-1 replication (24).  Our understanding of retroviruses’ high mutation 
rate (27) allowed us to understand why resistance to the NRTI’s arose so quickly, and 
further fueled efforts to uncover other vulnerabilities in the HIV-1 replication cycle that 
could be exploited for new treatments.  Inhibitors of the HIV-1 protease, reverse 
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transcriptase, envelope fusion inhibitors, and integrase inhibitors have developed from 
our increased understanding of the mechanisms of the retrovirus life cycle (10, 13, 14).  
 However, ultimately a vaccine will be needed to eradicate AIDS.  Currently, there 
are theories that potent enough antiretroviral therapy could eradicate HIV-1 infection 
from a single human host (20); however the cost of curing even one infection is likely too 
expensive to be a viable option where cures are needed the most, such as Africa.  Vaccine 
research is fraught with scientific and ethical difficulty as we lack a reliable animal model 
for testing vaccines. 
   In addition to HIV-1, which has had a huge impact on human ecology, other 
retroviruses are also important etiologic agents for cancers.  MLV, Jaagsietke Sheep 
Retrovirus (JSRV), HTLV-1, and many others are known to cause cancer in human and 
animal hosts (7, 11, 17, 25).  Understanding of how these viruses interact with and 
exploit weaknesses in hosts is crucial to developing strategies for preventing disease.  
One promising potential might be to develop vaccines against the viruses that cause 
cancers.  This idea has been proposed before, however no effective vaccine against a 
cancer caused by a retrovirus has been developed. 
The ability of simple retroviruses to rapidly infect mitotically active cells can also 
be exploited to treat disease (6).  Use of retroviruses as gene therapy vectors has not been 
without controversy, however, and further research is needed to develop retroviruses into 
an effective and widely affordable gene therapy modality. 
Clearly, the importance of retrovirus research cannot be understated.  Given the 
huge impact retroviruses have on biology from the microcosm of the cell to human and 
animal ecology, the scientific community has a huge task set before it to understand 
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retroviruses fully enough to counteract diseases caused by infection, and hopefully, one 
day harness their potential as curative agents.   
 The work presented in these three chapters has investigated three aspects of 
retrovirus biology.  All studies have utilized a helper cell line/retrovirus vector system to 
study mechanisms of replication in one complete life cycle of either MLV or SNV (23).  
All studies looked at the effects of modifying certain properties of either viral proteins or 
viral vectors to examine their effects on virus biology.  Therefore, even though three 
divergent aspects of viral biology were probed in this work, strategies employed for these 
investigations were quite similar.   
 In the first aim, the specific sequence requirements for the R region in retrovirus 
minus strand DNA transfer were examined.  It had been debated whether or not the 
specific sequence content of the ‘R’ region was necessary for successful minus strand 
DNA transfer (2, 3, 33).  By substituting the native of viral ‘R’ sequence with gene 
fragments, we proved that not only was homology a sufficient factor for minus strand 
DNA transfer in MLV-based retrovirus vectors, but that minus strand DNA transfer could 
be used to reconstitute functional genes in the DNA proviruses (5). 
 In addition to establishing the ability of non-viral sequences to mediate minus-
strand DNA transfer, the experimental system described in the first chapter supported 
mechanistic findings of others in reverse transcription.  The first mechanism is that of 
read-through transcription.  This phenomenon, first described in 1987, is the occasional 
suppression of the termination signal in the LTR of retroviruses, which can lead to 
incorporation of host sequences into the retrovirus genome (15).  In previous studies, this 
was discovered to be a mechanism for oncogene transduction and activation.  In our 
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system, read-through transcription lead to incorporation of an additional downstream 
PBS sequence that was contained in the original vector used to transfect virus-producing 
cells (29).  This additional PBS, located downstream of the 3’ U5 of the retroviral vector, 
allowed reverse transcription to initiate on the 3’ end of the vector instead of the 5’ LTR, 
bypassing minus-strand DNA transfer altogether, leading to a specific sequence finding 
on analysis of the provirus’ 5’ LTRs.  LTRs from proviruses that had resulted from 
reverse transcription initiating from a 3’ PBS contained 100% homology with the 3’ LTR 
in the viral vector, which could only occur if minus-strand DNA transfer was bypassed in 
this manner.  The frequency with which this phenomenon occurred (18%) agreed with the 
frequency found by others. 
 The second mechanism of retrovirus reverse transcription found in our system 
was that of read-in transcription.  First described by Dang and Hu (8), this phenomenon 
arises when the transfected retroviral vector is integrated into the producer cells 
downstream of a cellular promoter that is stronger than the retroviral U3 promoter.  This 
leads to incorporation of extra sequences upstream of the retroviral R region that begins 
the viral RNA transcripts.  In the minus-strand gene reconstitution vectors, this generated 
viral transcripts that carried an extra region of homology (a 5’ U3), which allowed the 
virus to use the U3 region to mediate minus-strand DNA transfer.  Sequence analysis of 
proviruses that resulted from read-in transcription revealed LTRs that contained 100% 
homology with the 5’ LTR of the viral vector. 
The minus-strand transfer gene reconstitution vectors derived to establish the role 
of non-viral sequences in minus strand DNA transfer could be adapted as a new self-
activating gene therapy vector.  Ultimately, a suicide gene (18) could be divided into two 
 172
fragments that contain overlapping homology, and inserted into the MLV vector.  A virus 
carrying the vector with the suicide gene could be used to infect cells in a mitotically 
active tumor, and once infected, reverse transcription would reconstitute the lethal gene 
in the infected tumor cells and cause cell death, hopefully leading to eradication of the 
cancer.  A significant number of malignant tumors contain highly mitotically active cells; 
presumably an MLV vector would be ideal as a cancer therapy vector because MLV 
vectors can only infect actively dividing cells.   
In addition to applications in gene therapy, this system could be used to test for 
mobilization of retroviruses in cell culture systems.  Retroviral enzymes in the cell 
population would mobilize vectors carrying gene fragments and effective activity of these 
retroviruses could be monitored by expression of the reconstituted gene in a one-round 
replication assay, rather than traditional use of lengthy co-culture assays.   
The significance of these results is threefold.  First a new gene therapy principle 
was proven.  Secondly, the nature of the mechanism of minus strand DNA transfer was 
more fully elucidated, and finally, a vector to test for the mobilization of retroviruses in 
cells was established.  In addition to these findings, variations in viral RNA transcription 
were observed that accounted for some of the provirus forms observed in these 
experiments. 
  In the second aim, mechanisms of reverse transcription were investigated.  
Specifically, the genetic relationships between two distantly related retroviruses- MLV 
and SNV, were investigated by determining complementation relationships between 
various domains of the Pol gene.  Multiple roles of IN have been elucidated for MLV and 
HIV replication; IN is vital for particle maturation, reverse transcription, and integration 
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of the viral DNA into the host chromosome.  It has been proven that the HHCC domain 
of IN specifically for HIV-1 is necessary for HIV-1 reverse transcription (31), and it has 
been proposed that it is the C-terminal end of MLV IN is required for reverse 
transcription in MLV (21).  A functional role of SNV IN during reverse transcription has 
not been described.  The experimental system in the second aim was designed to 
determine if MLV IN proteins could complement either SNV or MLV RT to complete 
replication.  Chimera SNVgagMLVpol vectors were expressed and the ability of these 
chimera gag-pol molecules to assemble into virions with SNVgag-pol molecules was 
proven.  The system was based on vectors designed to examine co-packaging of SNV and 
MLV RNA (4).   
Specific mutations were introduced into the Pol gene to make SNVRT+IN- and 
SNV RT-IN+ vectors.  MLV RT+IN- and MLV RT-IN+ vectors were synthesized by 
introducing specific mutations into the pol of a chimeric SNVgagMLVpol expression 
construct.  To make the RT-IN+ constructs, the residues in the catalytic core were 
substituted to inactivate the RT polymerase (SR7-D150E for MLV and YVNN for SNV).  
Two RT+IN- vectors were constructed for SNV and MLV.  A four-amino acid insertion 
in the HHCC motif was made to disrupt the zinc finger of the SNV and MLV IN for two 
of the vectors (SR8 for SNV and LC2 for MLV), and a catalytic core substitution was 
made to disrupt the enzymatic activity of IN for the other two vectors (SR12 and SR13 
for SNV and MLV, respectively).  Therefore, the vectors with inactivated IN should 
contain a biologically active RT, and the vectors with inactivated RT should contain 
biologically active IN. 
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 The ability of SNV Pol proteins to interact and co-assemble with MLV Pol 
molecules was established.  These results showed that level of complementation of the 
MLV RT -IN+ vector were the same for SNV RT+IN- and MLV RT+IN-, indicating that 
SNV and MLV RT proteins can interact equally well with MLV IN. 
Furthermore, two different functions of IN have recently been elucidated; these 
functions impacted the ability of SNV and MLV IN to interact with MLV RT in this 
system.  The level of complementation was greater for the RT+IN- HHCC mutation than 
for the RT+IN- catalytic core substitution mutant following normalization for RT activity.  
Because the RT+IN- HHCC IN insertion mutant had a processing defect, it produced less 
RT, and therefore its level of complementation was higher when corrected for RT activity 
than the RT+IN- catalytic core mutants, which had no processing defect. 
The SNV and MLV IN HHCC insertion mutants were deficient in RT activity, 
which correlated with a processing defect seen in these mutants.  Therefore, our results 
do not definitively demonstrate a role for SNV or MLV IN during reverse transcription of 
MLV RNA; however, participation of these proteins in reverse transcription cannot be 
ruled out on the basis of these results.  Our results showed no difference in the ability of 
MLV IN to rescue reverse transcription or integration in an SNV or MLV RT+IN- 
construct.  This strongly suggests that several crucial RT-IN interactions are conserved 
between SNV and MLV.  These results indicate that protein interactions in the reverse 
transcription and pre-integration complexes for MLV and SNV are conserved, and that 
the individual proteins can interact with other distantly related retroviral proteins. 
The C-terminal region of IN encompassing residues 345-365 of MLV has nearly 
100% sequence identity with residues 329-349 of SNV IN (Figure 1); this could comprise 
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a region of IN that contains the crucial contacts that allow for the interchangeability of 
SNV and MLV IN.  This is of significance because it highlights a possible mechanism for 
evolution of new species of retroviruses, and perhaps viruses with increased 
pathogenecity or immune evasion for the host.  Future studies to explore IN and RT 
complementation between SNV and MLV could investigate the role of these conserved 
amino acids in reverse transcription and replication.  Establishing cell lines from single 
cell clones expressing the MLV RT mutant may improve complementation; this was 
necessary for other studies investigating MLV RH and RT complementation (16).  
Complementation between MLV and SNV Pol proteins cannot be further evaluated 
without improving the sensitivity of the assay.  Various strategies were employed to 
attempt improvement of this system, including transient transfection assays and 
concentrating virus pseudotyped with vesicular stomatitis virus G (VSV-g) envelope 
prior to complementation titer measurement (32). 
Specifically, the work presented in AIM 2 has furthered understanding of 
interactions between Pol molecules occurs, which may provide insight into mechanisms 
of retrovirus evolution.  It is thought that SNV may have arisen from a recombination 
event between MPMV and GaLV .  This recombination could not have taken place if a 
cell infected with both viruses had not expressed viral proteins that were able to interact 
with non-homologous viral RNA.  In essence, the system in the second aim required the 
interaction of SNV and MLV viral proteins for effective replication.  The fact that 
replication did occur with these two species forced cooperation underscores the genetic 
flexibility of these two simple retroviruses.  
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In the last aim, mechanisms of MLV assembly were investigated, specifically the 
contribution of a newly described region at the 3’ end of CA.  This region, termed the 
‘Charged assembly helix’, was necessary for assembly of mature MLV viral particles.  
Furthermore, this region, consisting of highly charged acidic and basic residues, was 
widely conserved among gammaretroviruses, except for SNV.  Interestingly, similar 
motifs are not easily observed in other retrovirus subgroups.  The minimum length of 
CAH sequence necessary for efficient assembly was not determined, as the shortest 
deletion that did not work was a 13-amino acid deletion, while the longest deletion with 
wild-type phenotype was a 22 amino acid deletion.  These results implied a highly 
ordered structural component to the charged assembly helix, and modeling studies were 
undertaken to elucidate its properties.  A helical structure was postulated, and further 
experimental testing supported this proposal.  Based on this hypothesis, structural 
modeling revealed a conserved cluster of neutral amino acids oriented in a similar way on 
all working charged assembly helix mutants.  Follow-up studies of charged assembly 
helix function will further test the hypothetical alpha helical structure by analyzing the 
CD spectra of the charged assembly helix to determine the relative amount of alpha-
helical structure contributing to the charged assembly helix.   
Another possible function of the charged assembly helix that needs to be 
evaluated is its involvement in the recruitment of envelope proteins. 
  Such disparity exists between the defective charged assembly helix mutants and 
the functional charged assembly helix mutants that future studies should attempt to more 
finely define the mechanisms and role(s) of the charged assembly helix in MLV 
maturation.  Specifically, the replication incompetent charged assembly helix mutants 
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were severely deficient in budding, virus production, and capsid maturation, as well as 
particle size regulation.  This finding suggests an important function of the charged 
assembly helix early in the assembly process that all subsequent assembly steps depend 
upon.  One possibility is that the highly ordered alpha helix formed by the charged 
assembly helix is essential for early Gag-gag interactions.  It is tempting to speculate that 
the arrangement of the charged residues in the charged assembly helix is necessary for 
tight packing of Gag molecules together during assembly.  The modeled charged 
assembly helix alpha helix contained alternating bands of positive and negative amino 
acids that could interact intermolecularly with charged assembly helix regions on other 
Gag proteins, pulling the Gag particles closely together.  This theory is supported by the 
following findings.  The replication-defective charged assembly helix mutants form virus 
particles that are, on average, much larger than wild type and lose their ability to tightly 
regulate virus particle size.  This potentially implies a problem with condensation of the 
Gag proteins, which could easily be caused by charge-charge repulsions and steric 
inhibitions.  Secondly, the charged assembly helix viruses that do get released are 
efficiently processed to their appropriate Gag protein components, which suggested that 
the charged assembly helix was also important in condensation of the virus core and not 
proteolytic processing, since even though processing occurs no mature particles were 
observed on EM.  Thirdly, deletion of the 33 amino acids in the charged assembly helix 
seriously impaired virus production.  This finding mapped a crucial assembly determinant 
to the charged assembly helix.   
One weakness of the proposal that the charged assembly helix is involved in 
intermolecular Gag-Gag interactions is the fact that SNV, a related gammaretrovirus, 
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lacks a highly charged domain.  Structural predictions do suggest a highly alpha-helical 
structure to the C-terminus of SNV CA (Figure 2); however, it is not comprised of highly 
charged residues and it is therefore unlikely to utilize charge-charge attractions to bring 
Gag molecules together.  This suggests that either SNV has an entirely different 
mechanism for Gag:Gag interactions during assembly, or that it has the same mechanims 
of Gag-gag interactions, but accomplishes assembly via mechanisms that do not require 
charged amino acids. 
Structural studies are done with great difficulty, however, and care must be taken 
when proposing structural models in the absence of objective data.  Algorithms for 
structure prediction are simply based on previously proven structures; these are not 
always predictive of actual new structural findings.  In addition, although this sequence is 
highly conserved in gammaretroviruses, SNV lacks an charged assembly helix, which 
indicates that there must be ways at least one gammaretrovirus can fulfill the role of the 
charged assembly helix without an charged assembly helix-like sequence.   
Perhaps the most interesting finding of these studies is the apparent correlation 
with the charged assembly helix domain and the roles of the p2 in HIV-1 and the spacer 
peptide (SP) in RSV.  An alpha-helical structure has been proposed for the p2 of HIV-1, 
and deletion of this region results in mutants with structural similarities to our charged 
assembly helix mutants (1).  In addition, deletion of the SP in RSV results in a similar 
phenotype for RSV; however, an alpha-helix structure for this peptide has not been 
established (19). 
Regardless of what the structure of the charged assembly helix is eventually 
determined to be, this region has identified a new crucial determinant in MLV assembly, 
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and future studies of this region will likely provide great advances in our understanding 
of retrovirus assembly.  Ultimately, it will be very important to elucidate the differences 
between SNV and MLV assembly and to determine what sequence(s) in SNV Gag 
polyproteins carry out the analogous function of the MLV charged assembly helix.  
In summary, the work presented in this dissertation provided major insights into 
mechanisms of retrovirus reverse transcription and assembly.  The first work established 
a proof-of-principle for a novel retrovirus gene therapy vector and proved that non-viral 
sequences can mediate minus-strand DNA transfer.  The second aim established for the 
first time that MLV and SNV Pol proteins could interact and replicate as long as the Gag 
proteins are derived from SNV.  Finally, the third aim identified a region in CA crucial 
for MLV assembly and proposed a working model for its function, which provides a 
framework upon which future studies can further dissect the role of the charged assembly 
helix in MLV biology.     
In closing, the three works presented here have made important contributions to 
the current base of knowledge of retrovirus biology and have opened up new and 
interesting questions for further study.  
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FIGURE LEGENDS 
 
Figure 1: Multiple sequence alignment of SNV and MLV Integrase.  SNV Integrase is 
shown on the top line and MLV Integrase is on the bottom line.  Asterisks denote areas of 
identity.  The red letters denote an area of high homology between SNV and MLV IN 
near the C-terminal region of integrase. 
 
Figure 2:Chou-Fasman structure prediction values for SNV CA.  The sequence is given 
in the top line.  The actual predictor number is given in the second line; any value >1.0 is 
strongly predictive of an alpha helix.  The third line shows the predicted structure for 
each amino acid.  Capital ‘B’ denotes strong beta sheet-forming, Capital ‘H’ denotes 
strong alpha-helix forming.  Lower-case ‘i’ denotes an indifferent predictor value, and 
capital ‘I’ denotes slightly in favor of forming a helix.  Lower-case ‘h’ predicts helix 
formation, lower-case ‘b’ denotes slight beta-sheet formation. 
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SNV Capsid Chou-Fasman Structure prediction 
p l r e t g e r d m t g r p m r t y v p f t t s d l y n w k n q n p s  
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f s q a p d e v i s l l e s v f y t h q p t w d d c q q l l r t l f t  
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0.83 0.98 0.57 1.01 1.08 0.77 0.57 1.08 1.01 0.57 0.98 1.42 0.57 1.51 0.67 1.11 1.42 1.42 1.08 1.06 1.08 1.11 1.13 1.06 0.77 1.11 0.77 1.42 0.57 1.01 1.08 0.98 1.16 1.16 1.08 1.11
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 Figure 2. 
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APPENDIX 
 
Cloning Strategies for Charged Assembly Helix Mutants.  Construction of the CAH 
mutants was done with PCR mutagenesis of vector pWZH30, an MLV gag-pol 
expression vector.  Two primers were designed to amplify the region for mutagenesis in 
each new mutant, and then two primers containing the mutated sequence were designed 
for use with these primers.  The cloning strategy will be explained in detail for the 
cloning of pSR33; the table below includes the primer sequences for pSR33 and the other 
mutants constructed in this project.   
 To make a 33-amino acid deletion in pWZH30 to make pSR33, a two-step PCR 
reaction was needed.  Using pWZH30 as a template, the first PCR reactions amplified bp 
1885-2440 in pWZH30 and bp 2440-2951.  The primers used for the former reaction 
were P7MCA (5’ CGGTGCGGGGCGATGATGGGC 3’) and delEWrev (5’ 
CCAAAAGCTTGCTCATCTCTCTATGCGGGGTTTCTCGTTTATTAAAG 3’).  
These primers amplified the region 1885-2440.  The latter reaction was done with 
primers RPM2951 (5’ AACCTGAGCTCCTGATCCCTC 3’) and delEWfor 
(5’GCATAGAGAGATGAGCAAGCTTTTGGCCACTGTCGTTAGTGGA 3’).  The products 
obtained from these reactions were purified and amplified together with primers P7MCA 
and RPM2951.  The resulting fragment was 0.9 kb in length.  This fragment was digested 
with ClaI and XhoI.  The fragment was ligated into pWZH30 backbone that had been 
digested with ClaI and XhoI and treated with calf intestinal phosphatase.  All resulting 
mutants were sequenced on both strands to verify that the correct sequence had been 
mutated.  In the table below, the primers used to construct the remaining mutants as well 
as the mutations that resulted are detailed. 
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 Mutant 
Name 
CAH sequence Forward 
Primer 
Reverse 
Primer 
Wild 
Type 
peereerirreteekeerrrtedeqkekerdrrrhremskll   
PSR33 p---------------------------------hremskll EWdelfor EWdelrev 
SR11 peereerirreteekeer-----------rdrrrhremskll EW11aaF Raa11DWE
SR15 peereerirretee---------------rdrrrhremskll EWD15aaF Raa51DWE
EW-13 peereerirrete—-eer-----------rdrrrhremskll EW-17-
1for 
EW17-1-
rev 
EW-19-
1 
peereerirrete-------------------rrhremskll EW19-1-
for 
EW19-1-
rev 
EW 19-
2 
pee----irretee---------------rdrrrhremskll EWdel19-2-
for 
EWdel19-2-
rev 
EW18 pe-------reteekeer-----------rdrrrhremskll   
    
EW22U PEEREERIRRET----------------------HREMSKLL   
EW22D PEEREERIRRETE----------------------REMSKLL   
EW17-
3res 
PEEREERIRRETEE-----------------RERHREMSKLL EWdel19-2-
for 
EWdel19-2-
rev 
EW20  EW21-2-
for 
EW21-2-
rev 
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Table 1. Primers used to construct EW mutants  
Primer Name Sequence 
P7MCA 5’ cgg tgc ggg gcg atg atg ggc-3’ 
RPM2951 5’ aac ctg agc tcc tga tcc ctc-3’ 
EWdelfor 5’-gca tag aga gat gag caa gct ttt ggc cac tgt cgt tag tgg act tta ata aac gag aaa 
ccc cgc ata gag aga tga gca agc ttt tgg cca ctg tcg tta gtg ga-3’ 
EWdelrev 5’ cca aaa gct tgc tca tct ctc tat gcg ggg ttt ctc gtt tat taa ag- 3’ 
EWD15aaF 5’-aga gat cgt agg aga cat aga gag atg agc aag ctt tta gcc act gtc gtt agt gga cag-
3’ 
Raa51DWE 5’-aag ctt gct cat ctc tct atg tct cct acg atc tct ttc ctc tgt ttc tct cct gat acg ttc c-
3’ 
EW11aaF 5’-aga gat cgt agg aga cat aga gag atg agc aag ctt ttg gcc act gtc gtt agt gga c-3’ 
Raa11DWE 5’-aag ctt gct cat ctc tct atg tct cct acg atc tct gcg ttc ttc ttt ttc ctc tgt ttc tct cc-3’ 
EW-17-1for 5’-cga gaa acc cct  gag gaa aga gag gaa cgt atc agg aga gaa aca gag gaa gaa cgc 
aga gat cgt agg-3’ 
EW17-1-rev 5’-acg atc tct gcg ttc ttc ctc tgt ttc tct cct gat acg ttc ctc tct ttc ctc agg gg-3’ 
EW19-1-for 5’-cga gaa acc cct gag gaa aga gag gaa cgt atc agg aga gaa aca gag agg aga cat 
aga gag atg agc aag cta ttg gcc-3’ 
EW19-1-rev 5-ggc caa tag ctt gct cat ctc tct atg tcc cct ctc tgt ttc tct cct gat acg ttc ctc tct ttc 
ctc ag-3’ 
EW21-2-for 5’-gaa aaa att ttt aat aaa cga gaa acc ccg gaa aga gaa aca gag gaa aaa gaa gaa 
cgc aga gat cgt agg aga cat aga gag atg agc-3’ 
 
EW21-2-rev 5’-gcg ttc ttc ttt ttc ctc tgt ttc tct ttc cgg ggt ttc tcg ttt att aaa aat ttt ttc-3’ 
 
EW17-3res-for 5’ cct gag gaa aga gag gaa cgt atc agg aga gaa aca gag gaa aga gag aga cat aga 
gag atg agc aag cta ttg gcc 
EW17-3res-rev 5’ gct cat ctc tct atg tct ctc tct ttc ctc tgt ttc tct cct gat acg ttc c-3’ 
EW22-U-for 5’ tc ttt aat aaa cga gaa acc cct gag gaa aga gag gaa cgt atc agg aga gaa aca agg 
aga cat aga gag atg agc aag cta ttg gcc 3’ 
EW22-U-rev 5’  act aac gac agt ggc caa tag ctt gct cat ctc tct atg tct cct tgt ttc tct cct gat acg 
ttc ctc tct ttc c-3’ 
EW22-D-for 5’ tc ttt aat aaa cga gaa acc cct gag gaa aga gag gaa cgt atc agg aga gaa aca gag 
agg aga aga gag atg agc aag cta ttg gcc 3’ 
EW22-D-rev 5’  act aac gac agt ggc caa tag ctt gct cat ctc tct tct cct ctc tgt ttc tct cct gat acg 
ttc ctc tct ttc c-3’ 
EWdel19-2-for 5’-agg cag aaa ttt aaa ttt tta ata aac gag aaa ccc cgg aag aaa tca gga gag aaa cag 
agg aaa gag atc gta gg-3’ 
EWdel19-2-rev 5’-tcc tac gat ctc ttt cct ctg ttt ctc tcc tga ttt ctt ccg ggg ttt ctc gtt tat taa aaa ttt 
ttt ctg cc- 3’ 
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Data from unpublished mutant 19-2. 
Mutant 19-2 is not replication-competent.   293T cells were transfected with 19-2, 
SR2, and mlv-env expressing plasmids.  Virus was harvested from the supernatants of the 
transfected cells and used to infect D17 cells.  Five independent experiments with 19-2 
were conducted.  Four of the infections showed that 19-2 produced a titer of <1 cfu/mL 
(Table 1A and B).  The fifth experiment was used for RNA packaging studies only, so 
titers were not measured with this set.  A portion of the virus from each experiment was 
also used to measure the RT activity of the virus.  For each experiment, the RT activity of 
mutant 19-2 was not significantly above background.  The average RT activity for all five 
experiments was 0.6%.  This indicates therefore that mutant 19-2 was not replication 
competent.   
Table 1A. 
Titers number of exp. titer, cfu/mL RT assay, % wt 
    
SR2 6 <1 0% 
WZ30 5 (avg 4) 8.6 X 103 100% 
SR33 5 <1 0.2% 
SR11 3 (avg 2) 4 X 103 400% 
SR15 4 (Avg 3) 2 x 104 88% 
FeEW 3 (avg 2) 3 x 104 126% 
17-2 4 (avg 3) <1 0 
17-3 4 (avg 3) <1 0 
19-1 4 (avg 3)1.3 X 104 1140% 
19-2 5 <1 0.6% 
21-1 3 <1 1% 
13-1 2 <1 1% 
18-2 2 <1 1% 
Table 1B 
Exp #/date Vector RT Assay % wt RT activity Titer
2/11/02 19-2 5354 0 <1
2/5/02 19-2 11177 1%  
4-14-02 19-2 2414 0 <1
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4-8-02 19-2 5022 2% <1
3-24-02 19-2 6290 0 ND
The budding properties of mutant 19-2 are different from wild type and other EW 
mutants.  Following transfection of 293T cells, a portion of transfected cells were sent 
for electron microscopy analysis.  Five pictures of cells producing vector 19-2 were 
obtained.  Unlike the other replication-incompetent EW mutants, 19-2 maintains an 
ability to form wild-type sized particles.  However, several particles were observed 
to be apparently budding into the cell, instead of to the extracellular space. 
 
EM Images of 19-2 
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 19-1 
 
 
17-3 
plgps 
Western on cell lysates for 19-2:  
 
Westerns on Virus Lysates 
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